tmo gaap othernonoperatingincomeexpenseus gaap othernonoperatingincomeexpenseus gaap othernonoperatingincomeexpenseus gaap othernonoperatingincomeexpenseus gaap othernonoperatingincomeexpenseinvestments measured net asset value per share equivalent practical expedient classified the fair value hierarchy gaap otherliabilitiescurrentus gaap otherliabilitiescurrentus gaap otherliabilitiesnoncurrentus gaap otherliabilitiesnoncurrentus gaap otherassetsnoncurrentus gaap otherassetsnoncurrentus gaap sellinggeneralandadministrativeexpenseus gaap otherassetscurrentus gaap otherassetsnoncurrenttmo gaap usdxbrli gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap cumulativeeffectperiodofadoptionadjustmentmemberus gaap gaap accumulatedothercomprehensiveincomemembersrt gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap cumulativeeffectperiodofadoptionadjustmentmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap cumulativeeffectperiodofadoptionadjustmentmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap buildingandbuildingimprovementsmembersrt gaap buildingandbuildingimprovementsmembersrt gaap machineryandequipmentmembersrt gaap machineryandequipmentmembersrt gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap cumulativeeffectperiodofadoptionadjustmentmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap customerrelationshipsmembertmo gaap developedtechnologyrightsmembertmo gaap developedtechnologyrightsmemberus gaap gaap tradenamesmembertmo gaap gaap gaap gaap gaap gaap customerrelationshipsmembertmo gaap gaap developedtechnologyrightsmembertmo gaap developedtechnologyrightsmemberus gaap gaap gaap tradenamesmembertmo gaap gaap inprocessresearchanddevelopmentmemberus gaap gaap gaap gaap gaap gaap disposalgroupheldforsalenotdiscontinuedoperationsmembertmo gaap disposalgroupheldforsalenotdiscontinuedoperationsmembertmo gaap disposalgroupheldforsalenotdiscontinuedoperationsmembertmo gaap disposalgroupheldforsalenotdiscontinuedoperationsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap minimummemberus gaap maximummemberus gaap gaap gaap minimummemberus gaap maximummemberus gaap gaap gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembersrt gaap otherpostretirementbenefitplansdefinedbenefitmembersrt gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembertmo usequityfundsmembercountry internationalequityfundsmemberus gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmembercountry gaap pensionplansdefinedbenefitmembersrt minimummemberus gaap equityfundsmemberus gaap gaap pensionplansdefinedbenefitmembersrt maximummemberus gaap equityfundsmemberus gaap gaap pensionplansdefinedbenefitmembersrt minimummemberus gaap fixedincomefundsmemberus gaap gaap pensionplansdefinedbenefitmembersrt maximummemberus gaap fixedincomefundsmemberus gaap gaap pensionplansdefinedbenefitmembersrt minimummemberus gaap hedgefundsmemberus gaap gaap pensionplansdefinedbenefitmembersrt maximummemberus gaap hedgefundsmemberus gaap multiassetfundsmemberus gaap pensionplansdefinedbenefitmembersrt minimummemberus gaap multiassetfundsmemberus gaap pensionplansdefinedbenefitmembersrt maximummemberus gaap gaap pensionplansdefinedbenefitmembersrt minimummembertmo alternativeinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmembersrt maximummembertmo alternativeinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativemembersrt minimummemberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativemembersrt maximummemberus gaap gaap pensionplansdefinedbenefitmembertmo usequityfundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry internationalequityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap fixedincomefundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap moneymarketfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap moneymarketfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmemberus gaap equityfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap equityfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap fixedincomefundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap hedgefundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap hedgefundsmemberus gaap multiassetfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap multiassetfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmembertmo alternativeinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembertmo alternativeinvestmentsmemberus gaap insurancecontractsmemberus gaap pensionplansdefinedbenefitmemberus gaap insurancecontractsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplancashandcashequivalentsmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmembertmo usequityfundsmembercountry gaap pensionplansdefinedbenefitmembertmo usequityfundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry internationalequityfundsmemberus gaap pensionplansdefinedbenefitmembercountry internationalequityfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap fixedincomefundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap moneymarketfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap moneymarketfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmemberus gaap equityfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap equityfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fixedincomefundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap fixedincomefundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap hedgefundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap hedgefundsmemberus gaap multiassetfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap multiassetfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanderivativememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmembertmo alternativeinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembertmo alternativeinvestmentsmemberus gaap insurancecontractsmemberus gaap pensionplansdefinedbenefitmemberus gaap insurancecontractsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplancashandcashequivalentsmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap gaap gaap gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap commercialpapermembertmo gaap commercialpapermembertmo gaap gaap gaap gaap seniornotesmemberus gaap gaap netinvestmenthedgingmemberus gaap gaap gaap gaap seniornotesmemberus gaap subsequenteventmembertmo gaap seniornotesmemberus gaap gaap seniornotesmemberus gaap subsequenteventmembertmo gaap gaap gaap costofsalesmembertmo analyticalinstrumentsmemberus gaap gaap gaap gaap financialguaranteemembertmo minimummembertmo maximummembertmo gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap gaap gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap gaap fairvaluehedgingmemberus gaap gaap fairvaluehedgingmemberus gaap gaap netinvestmenthedgingmemberus gaap gaap gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap gaap designatedashedginginstrumentmemberus gaap othernoncurrentassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap othernoncurrentliabilitiesmemberus gaap gaap othercurrentassetsmemberus gaap foreignexchangecontractmemberus gaap gaap othercurrentassetsmemberus gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap nondesignatedmemberus gaap gaap foreignexchangecontractmemberus gaap nondesignatedmemberus gaap gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap interestrateswapmemberus gaap gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap interestrateswapmemberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmembertmo foreigncurrencydenominateddebtmemberus gaap gaap designatedashedginginstrumentmembertmo foreigncurrencydenominateddebtmemberus gaap gaap designatedashedginginstrumentmemberus gaap netinvestmenthedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap netinvestmenthedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap netinvestmenthedgingmemberus gaap otherexpensememberus gaap gaap designatedashedginginstrumentmemberus gaap netinvestmenthedgingmemberus gaap otherexpensememberus gaap gaap costofsalesmemberus gaap foreignexchangecontractmemberus gaap gaap costofsalesmemberus gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap otherexpensememberus gaap gaap foreignexchangecontractmemberus gaap otherexpensememberus gaap gaap otherexpensememberus gaap nondesignatedmemberus gaap gaap gaap interestrateswapmemberus gaap cashflowhedgingmemberus gaap gaap gaap gaap gaap gaap gaap subsequenteventmembertmo mesabiotechmemberus gaap subsequenteventmembersrt mesabiotechmemberus gaap subsequenteventmembersrt united state security exchange commissionwashington annual report pursuant section or the security exchange act of the fiscal year ended december or transition report pursuant to section or of the security exchange act of file number fisher scientific inc exact name of registrant specified in it charter state of incorporation employer identification third avenuewaltham massachusetts address of principal executive office zip code registrant telephone number including area code registered pursuant to section of the act title of classtrading symbol name of each exchange registeredcommon stock par valuetmonew york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock exchangesecurities registered pursuant to section of the act noneindicate check mark the registrant well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is not required to file report pursuant to section or of the act yes no indicate by check mark whether the registrant filed report required to filed by section or of the security exchange act of the preceding month and ha been subject to filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation during the preceding month yes no indicate by check mark whether the registrant is large accelerated filer accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company indicate by check mark whether the registrant ha filed report on and attestation to it management assessment of the effectiveness of it internal control financial reporting section of the sarbanes oxley act by the registered public accounting firm prepared or issued it audit report indicate by check mark whether the registrant is shell company defined in rule of the exchange act yes no of june the aggregate market value of the voting stock held by nonaffiliates of the registrant approximately based on the last reported sale of common stock on the new york stock exchange composite tape reporting system on june of february the registrant share of common stock outstanding document incorporated by referencesections of thermo fisher definitive proxy statement for the annual meeting of shareholder incorporated by reference part ii and iii of report thermo fisher scientific inc annual report on form kfor the fiscal year ended december table of contentspagepart iitem risk unresolved staff legal mine safety iiitem market for the registrant common equity related stockholder matter and issuer purchase of equity management discussion and analysis of financial condition and result of quantitative and qualitative disclosure market financial statement and supplementary change in and disagreement accountant on accounting and financial control and iiiitem director executive officer and corporate executive security ownership of certain beneficial owner and management and related stockholder certain relationship and related transaction and director principal accountant fee and ivitem exhibit and financial statement form fisher scientific inc part iitem businessgeneral development of businessthermo fisher scientific inc also referred to in this document thermo fisher the company or the registrant is the world leader in serving science mission is to enable our customer to make the world healthier cleaner and safer we serve customer working in pharmaceutical and biotech company hospital and clinical diagnostic lab university research institution and government agency well environmental industrial quality and process control setting our global team of more than colleague delivers an unrivaled combination of innovative technology purchasing convenience and pharmaceutical service our industry leading brand including thermo scientific applied biosystems invitrogen fisher scientific unity lab service and patheon we continuously increase our depth of capability in technology software and service and leverage our extensive global channel to address our customer emerging need we this through organic investment in research and development and through acquisition our goal is to make our customer more productive in an increasingly competitive business environment and enable to solve challenge complex research to improved patient care environmental and process monitoring and consumer safety forward looking statementsforward looking statement within the meaning of section of the security exchange act of the exchange act are made throughout this annual report on form statement contained herein that are not statement of historical fact may be deemed to be forward looking statement including without limitation statement regarding projection of revenue expense earnings margin tax rate tax provision cash flow pension and benefit obligation and funding requirement our liquidity position cost reduction restructuring activity new product and service development competitive strength or market position acquisition or divestiture growth decline and other trend in market we sell into new or modified law regulation and accounting pronouncement outstanding claim legal proceeding tax audit and assessment and other contingent liability foreign currency exchange rate and fluctuation in rate general economic and capital market condition the timing of any of the foregoing assumption underlying any of the foregoing the expected impact of the covid pandemic on the company business and any other statement that address event or development that thermo fisher intends or belief or may occur in the future without limiting the foregoing the word belief anticipates plan expects seek estimate and similar expression are intended to identify forward looking statement although not all forward looking statement are accompanied by such word the company may elect to update forward looking statement in the future specifically disclaims any obligation to do even if the company estimate change and reader not rely on those forward looking statement representing the company view of any date subsequent to the date of the filing of this report number of important factor could cause the result of the company to differ materially from those indicated by such forward looking statement including those detailed under the heading risk factor in part item business segment and productswe report our business in four segment life science solution analytical instrument specialty diagnostics and laboratory product and service in we worked with our customer to respond to the covid pandemic this important work crossed many of the business segment we describe early in the year cryo electron microscope made by our analytical instrument business used by researcher to create the first image of the virus through our research and safety market channel and healthcare market channel we were critical supplier of personal protective equipment ppe leveraging our strong relationship to secure product supply were scarce through our life science solution specialty diagnostics and laboratory product business we enabled widespread covid testing creating leading molecular diagnostic business in month to support hundred of million of polymerase chain reaction pcr test around the world and through our pharma service business we provided our pharma and biotech customer with the set of product and service needed to develop and produce vaccine and therapy life science solution segmentthrough our life science solution segment we provide an extensive portfolio of reagent instrument and consumables used in biological and medical research discovery and production of new drug and vaccine well diagnosis of infection and disease these product and service are used by customer in pharmaceutical biotechnology agricultural clinical fisher scientific inc business continued healthcare academic and government market life science solution includes four primary business bioscience genetic science clinical next generation sequencing and bioproduction biosciencesour bioscience business includes reagent instrument and consumables that help our customer conduct biological and medical research discover new drug and vaccine and diagnose infection and disease such covid our bioscience offering include reagent instrument and consumables used for protein biology molecular biology sample preparation and cell imaging and analysis the portfolio includes antibody and product for protein purification detection modification and analysis and sequencing detection and purification product used for high content analysis of nucleic acid many of these product are also used in applied market including agriculture forensics diagnostics product development toxicology research and diagnostic testing tool used for genetic engineering amplification quantification and analysis well rna isolation including stem cell reprogramming kit transfection reagent rna interference reagent along with gene editing tool and gene synthesis product cell culture medium reagent and plastic for preserving and growing mammalian cell which are used in many life science research application fluorescence based technology which facilitate the labeling of molecule for biological research and drug discovery these technology include wide range of cell analysis instrument including flow cytometers and imaging platform that enable fluorescence microscopy protein analysis product including pre cast electrophoresis gel for separating nucleic acid and protein and western blotting and staining tool genetic sciencesour genetic science business combine wide variety of instrument and related reagent used to provide high value genomic solution to assist customer decision in the research clinical healthcare and applied market our offering include real time pcr technology used to identify change in gene expression genotyping or protein on an individual gene by gene basis and for diagnostic testing to identify infection and disease such covid capillary electrophoresis ce sequencing core technology used in dna sequencing and fragment analysis and forensic analysis application and microarray technology used in gene expression genotyping and reproductive health our genetic analyzer served the foundational platform used to sequence the first human genome these system are used in variety of basic commercial and clinical research application clinical next generation sequencingour clinical next generation sequencing ng business focus on delivering simple fast and cost effective ng technology for range of application the business is focused on targeted sequencing solution for research use the application of ng in oncology and companion diagnostics bioproductionour bioproduction business support developer and manufacturer of biological based therapeutic and vaccine with portfolio of premium solution and service focused on upstream cell culture downstream purification analytics for detection and quantitation of process product impurity and suite of single use solution spanning the biologics workflow our bioproduction offering include single use bioproduction solution that provide our customer with faster turnaround and set time minimal validation requirement reduced investment and running cost and increased flexibility of manufacturing capacity production cell culture medium solution which are used by leading biotechnology and pharmaceutical company to grow cell in controlled condition and enable large scale cgmp current good manufacturing practice manufacturing of drug and vaccine we also provide our customer with the associated service to optimize the productivity of these production platform fisher scientific inc business continued chromatography product which deliver superior capacity and resolution for process scale bioseparations and offer broad set of scalable option for the purification of antibody antibody fragment and protein rapid molecular product that deliver accurate result in le than four hour for contaminant detection identification and quantitation scalable solution for the manufacture of cell therapy based drug our doe ingalls offering include chemical distribution and supply chain service that provide primarily life science manufacturer with reliable secure supply chain for their chemical raw material analytical instrument segmentthrough our analytical instrument segment we provide broad offering of instrument consumables software and service that are used for range of application in the laboratory on the production line and in the field these product and service are used by customer in pharmaceutical biotechnology academic government environmental and other research and industrial market well the clinical laboratory this segment includes three primary business chromatography and mass spectrometry chemical analysis and material and structural analysis chromatography and mass spectrometryour chromatography and mass spectrometry business provides analytical instrumentation for organic and inorganic sample analysis across applied technology and life science research these product are complemented by laboratory information management system lims chromatography data system cd database analytical tool automation system range of consumables such full line of chromatography column and range of sample preparation and separation product including auto sampler and multiplexing system chromatography is technique for separating identifying and quantifying individual chemical component of substance based on their specific physical and chemical characteristic our chromatography product line includes high performance liquid chromatography ion chromatography and gas chromatography system all of which are supported by our chromeleon chromatography data system software liquid chromatography lc system analyze complex sample matrix in liquid our high pressure liquid chromatography hplc and ultrahigh pressure liquid chromatography uhplc system offer high throughput and sensitivity and are sold either stand alone system or integrated with our mass spectrometer lc and lc these system are used for range of application from complex proteomic analysis to routine industrial quality assurance and quality control qa qc ion chromatography ic system separate ionic charged or highly polar molecule sugar and carbohydrate usually found in water based solution and typically detect them based on their electrical conductivity our ic product are used in wide range of application including scientific research and environmental testing well quality control in pharmaceutical food and beverage and other industrial process gas chromatography gc system analyze complex sample matrix in gas comprising both separation and detection technology separation technology is common to all gas chromatography analyzer and is paired with either conventional detector gc or with different type of mass spectrometer gc our gc offering includes triple stage quadrupole single stage quadrupole an orbitrap and an ion trap for range of application including food safety testing quantitative screening of environmental sample and complex molecular analysis elemental analysis spectrometer use atomic spectroscopy technique to identify trace concentration of element in liquid and solid sample primarily in environmental petrochemical food safety metallurgical geochemical and clinical toxicology research application these product are widely used in growth market such china india and latin america to support compliance with increasingly stringent international environmental and consumer safety regulation mass spectrometry is technique for analyzing chemical compound individually or in complex mixture by forming charged ion that are analyzed according to their mass to charge ratio in addition to molecular information each discrete chemical compound generates pattern that provides structurally identifiable information our comprehensive offering includes life science mass spectrometry system and inorganic mass spectrometry system well range of sample preparation and separation product including auto sampler and multiplexing system life science mass spectrometer include triple quadrupole and orbitrap technology our triple quadrupole system provide high performance quantitative analysis of chemical in biological fluid environmental sample and food fisher scientific inc business continued matrix they are also used by the pharmaceutical industry for targeted quantitation during drug discovery our orbitrap technology provide high resolution and accurate mass capability for both research and applied market and are well suited for drug metabolism proteomics environmental analysis food safety toxicology and clinical research application we also offer comprehensive portfolio of instrument control and data analysis software to help customer simplify their workflow and obtain knowledge from often complex data inorganic mass spectrometer include four product line isotope ratio mass spectrometry irms multi collector isotope ratio mass spectrometry mc irms inductively coupled plasma mass spectrometry icp and high resolution trace mass spectrometry hr trace these product are primarily used for qualitative and quantitative analysis of inorganic matter in range of application including environmental analysis material science and earth science chemical analysisour chemical analysis product fall into three main category material and mineral instrument field safety instrument and environmental and process instrument customer use these product to quickly and accurately analyze the composition of material to optimize workflow primarily in industrial application or to help them comply with governmental regulation and industry safety standard our product line range from those used on production line to improve quality and efficiency to portable system for rapid and real time chemical identification in the field or to analyze measure or respond to hazardous situation material and mineral instrument include production line process monitoring and control system for range of industrial application for example we offer on line instrument that analyze bulk material non invasively and in real time to improve quality control and ensure safe operation in mine or cement manufacturing plant well system that enable high speed weighing during bulk material handling we also offer gauging system that employ ionizing and non ionizing technology to measure the total thickness basis weight and coating thickness of flat sheet material such steel plastic foil rubber and glass we also offer on line analyzer based on variety of technology such ray imaging and ultra trace chemical detection to inspect packaged good for physical contaminant validate fill quantity or check for missing or broken part on line and at high speed in the food and beverage pharmaceutical production and packaging industry to maintain safety and quality standard field safety instrument are rugged handheld product that provide rapid precise real time analysis at the point of need our main product category are elemental analyzer optical analyzer and radiation detection instrument our portable elemental analyzer use ray fluorescence xrf or laser induced breakdown spectroscopy technology in qa qc application to identify metal alloy in scrap metal recycling in precious metal analysis in environmental analysis and for lead screening in range of consumer product our portable optical analyzer utilize raman fourier transform infrared ftir and near infrared nir technology for use in the field by first responder and law enforcement and military personnel need to quickly and accurately identify chemical and explosive in critical safety and security situation other application include qa qc in pharmaceutical production and identification of counterfeit drug our radiation measurement product are used to monitor detect and identify specific form of radiation in nuclear power environmental industrial medical and security application our primary customer include national regional and local government agency responsible for monitoring cargo vehicle and people traveling across border these product are also used by first responder in safety and security situation and for worker safety in the nuclear power and other industrial market environmental and process instrument include fixed and portable instrumentation that help our customer protect people and the environment well comply with government regulation and industry safety standard our product are used by environmental regulatory agency and power plant operator to measure ambient air and stack gas emission for compliance with regulated emission standard for criterion pollutant gas our product are also used in ambient particulate monitoring application by customer in mining environment to provide continuous measurement and logging of real time concentration and median particle size of airborne dust smoke mist and fume to improve efficiency and increase worker safety in addition to our broad product offering we offer variety of specialized service to our customer including equipment servicing instrument calibration service asset management and training material and structural analysisour material and structural analysis business includes electron microscopy molecular spectroscopy and laboratory elemental analysis instrument that are used by customer in life science material science and industrial market to accelerate breakthrough discovery fisher scientific inc business continued electron microscopy instrument include transmission electron microscope which provide imaging and characterization at the atomic scale with application in semiconductor development material science research and the characterization of protein structure and function we also offer scanning electron microscope which resolve feature from the optical regime to the nanometer length scale and are used for wide variety of application from material characterization in science and engineering to application in natural resource manufacturing and biological system our dualbeam focused ion beam scanning electron microscope system are used for sample preparation characterization nanoprototyping and industrial failure analysis our focused ion beam microscope are used in range of process control failure analysis and material research application we also offer electrical failure analysis instrument which are used in root cause failure analysis and quality control microct instrument which are micro computed tomography solution for quantitative analysis of broad range of material providing visualization of large volume non destructively and visualization software that turn the data and image generated by broad range of instrument into visualization of the microscopic sample allowing quantitative analysis of material property molecular spectroscopy instrument are divided into four primary technique ftir raman nir and ultraviolet visible uv vi spectroscopy these technology are typically used in the laboratory to provide information on the structure of molecule to identify verify and quantify organic material in pharmaceutical biotechnology polymer chemical and forensic science our material characterization instrument include rheometer and extruders that measure viscosity elasticity processability and temperature related mechanical change of various material we also provide range of surface analysis instrument commonly used in the semiconductor metal coating and polymer industry product development and failure analysis tool laboratory elemental analysis instrument and analyzer use ray fluorescence xrf ray diffraction xrd and arc spark optical emission oes technique for accurate and precise analysis of bulk material in the metal cement mineral and petrochemical industry specialty diagnostics segmentour specialty diagnostics segment offer wide range of diagnostic test kit reagent culture medium instrument and associated product in order to serve customer in healthcare clinical pharmaceutical industrial and food safety laboratory our healthcare product are used to increase the speed and accuracy of diagnosis which improves patient care in more cost efficient manner this segment ha five primary business clinical diagnostics immunodiagnostics microbiology transplant diagnostics and our healthcare market channel clinical diagnosticsour clinical diagnostics product include broad offering of liquid ready to use and lyophilized immunodiagnostic reagent kit calibrators control and calibration verification fluid in particular we provide product used for covid testing drug of abuse testing therapeutic drug monitoring including immunosuppressant drug testing thyroid hormone testing serum toxicology clinical chemistry immunology hematology coagulation glucose tolerance testing first trimester screening tumor marker testing and biomarkers testing for sepsis acute myocardial infarction and congestive heart failure we also private label many of our reagent and control for major in vitro diagnostics company through oem arrangement in many instance we will work with customer or partner to develop new product and application for their instrument platform we have developed one of the broadest menu for drug of abuse immunoassay we also provide broad offering of immunosuppressant drug immunoassay that be used on variety of clinical chemistry analyzer our clinical chemistry system include analyzer and reagent to analyze and measure routine blood and urine chemistry such glucose and cholesterol and advanced testing for specific protein therapeutic drug monitoring and drug of abuse our diagnostic test range currently cover approximately different validated method we also provide pre and post analytical automation for preparation of blood specimen and analysis and specialty diagnostic test based on patented biomarkers for sepsis cardiovascular and pulmonary disease well intensive care treatment and prenatal screening immunodiagnosticsour immunodiagnostics offering include developing manufacturing and marketing complete blood test system to support the clinical diagnosis and monitoring of allergy asthma and autoimmune disease in addition we offer antibody test for approximately indication to help diagnose autoimmune disease such rheumatoid arthritis celiac disease lupus and scleroderma our product include immunocap for allergy and asthma test and elia for autoimmunity test fisher scientific inc business continued microbiologyour microbiology offering include dehydrated and prepared culture medium collection and transport system instrumentation and consumables to detect pathogen in blood diagnostic and rapid direct specimen test quality control product and associated product for the microbiology laboratory our product help customer worldwide to diagnose infectious disease determine appropriate antimicrobial therapy implement effective infection control program and detect microbial contamination of their product or manufacturing facility within the food and pharmaceutical industry our product are used to assure the safety and quality of consumer product by monitoring production environment raw material and end product for bacterial contamination and animal health in the dairy industry transplant diagnosticsour transplant diagnostics product include human leukocyte antigen hla typing and testing for the organ transplant market our diagnostic test are used by transplant center for tissue typing primarily to determine the compatibility of donor and recipient pre transplant and to detect the presence of antibody post transplant that can lead to transplant rejection these transplant diagnostic test are widely used across the transplant testing workflow to improve patient outcome our transplant diagnostic offering include several line of hla typing and antibody detection assay utilizing serological molecular enzyme linked immunosorbent assay elisa flow and multiplexing technology healthcare market channelour healthcare market channel offering include broad array of consumables diagnostic kit and reagent equipment instrument solution and service for hospital clinical laboratory reference laboratory physician office and other clinical testing facility these product are manufactured by thermo fisher and third party and are primarily used in clinical diagnosis we go to market through our expert sale force segment relevant printed collateral and digital content and state of the art website www fishersci com healthcare containing full product content for more than million product laboratory product and service segmentour laboratory product and service segment offer virtually everything needed for the laboratory our unique combination of self manufactured and sourced product and extensive service offering enables our customer to focus on their core activity and help them to be more efficient productive and cost effective the segment also includes comprehensive offering of outsourced service used by the pharmaceutical and biotech industry for drug development clinical trial logistics and commercial drug manufacturing we serve the pharmaceutical biotechnology academic government and other research and industrial market well the clinical laboratory through four key business laboratory product laboratory chemical research and safety market channel and pharma service laboratory productsour laboratory product are used primarily by pharmaceutical company for drug discovery and development and by biotechnology company and university for life science research to advance the prevention and cure of disease and enhance quality of life this offering consists of equipment accessory and service for sample preparation storage and protection and analysis laboratory equipment technology includes our leading laboratory refrigerator and freezer ultralow temperature freezer and cryopreservation storage tank for maintaining sample in cold environment to protect them from degradation we also offer temperature control product such heated bath circulators immersion cooler recirculating chiller water bath and dry bath in range of size temperature and configuration for life science analytical chemistry manufacturing and quality control application in addition we offer sample preparation and preservation equipment which protects our customer chemical and biological sample and support the growth of cell and organism in optimal condition such temperature carbon dioxide and humidity well incubator and related product we also offer centrifugation product which are used to separate biological matrix and inorganic material including microcentrifuges general use bench top centrifuge and floor model additionally we offer biological safety cabinet which enable technician to handle sample without risk to or their environment and without risk of cross contamination of sample water and laboratory product include water analysis instrument such meter electrode and solution for the measurement of ph ion conductivity dissolved oxygen turbidity and other key parameter in the lab and production line we also offer other laboratory equipment such water purification system shaker vacuum concentrators microbiological incubator oven furnace hotplate stirrer stirring hotplate and other related product fisher scientific inc business continued laboratory plastic essential include leading offering of laboratory pipette tip and complementary range of handheld and automated pipetting system supporting low through high throughput activity these product optimize productivity and ergonomics and ensure accurate result we also offer sample preparation and storage product such centrifugation consumables well vial and organization system for ultralow temperature and cryogenic storage with specific product designed for low protein binding and low dna binding and container for packaging life science and diagnostic reagent well for the storage and transport of bulk intermediate and active pharmaceutical ingredient additionally our offering include complete selection of clinical specimen collection product drug of abuse collection kit and environmental and food safety glass and plastic vial bottle and container plastic transfer pipette general purpose clinical laboratory consumables and container for breast milk collection storage and feeding primarily used in neo natal unit and by lactation specialist we also provide oem and custom kit assembly service for clinical and drug of abuse test kit laboratory chemicalsour laboratory chemical offering comprises broad range of chemical solvent and reagent supporting virtually every laboratory application from research to drug discovery and development and manufacturing this portfolio includes organic chemical used to synthesize new material essential laboratory chemical used by scientist to purify extract separate identify and manufacture product high purity analytical reagent bioreagents used in many different application from cell growth to detailed protein analysis novel chemical building block reactive intermediate and screening library used to accelerate drug discovery and precious metal salt and solution used in broad range of application highly specific reaction are desired we provide bulk volume of many product for scale up from research to development and customized service for chemical procurement processing production testing and packaging research and safety market channelour research and safety market channel serf academic pharmaceutical biotechnology government and industrial customer we go to market through our expert sale force segment relevant printed collateral and digital content in four language state of the art website www fishersci com containing full product content for more than million product and our global network of resellers and distributor we have an international network of warehouse in our primary market through which we maintain inventory and coordinate product delivery with specialized product vault and warehouse management system we are able to handle the complete range of product we offer to our customer our transportation capability include our dedicated fleet of delivery vehicle well parcel shipping capability that are closely integrated with our third party parcel carrier throughout the product delivery process we provide our customer with convenient access to comprehensive electronic system that offer automated catalog search product order and invoicing and payment capability our channel offer mix of product that are manufactured by thermo fisher by third party for on private label basis and by third party under their brand offered for sale exclusively through we also offer broad range of third party product representing leading industry brand name on non exclusive basis our research product include complete offering of laboratory product ranging from capital equipment and instrument to chemical to consumable product our safety product include clean room and controlled environment supply personal protective equipment firefighting military and first responder equipment and supply and environmental monitoring and sampling equipment our education product include science related and laboratory product for the and secondary education market in addition to our broad product offering we offer variety of specialized service to our customer through our unity lab service team including training equipment servicing and asset management and dedicated supply management personnel we also offer scientific support service including desktop delivery coordination of instrument calibration and service and on site customer service pharma serviceswe provide the entire spectrum of development manufacturing and clinical trial service for both small molecule and large molecule pharmaceutical this includes development of suitable formulation and manufacturing process for the active pharmaceutical ingredient api or biologic ii technology transfer to scale up the manufacturing iii labeling packaging distribution and logistics for clinical trial and iv commercial scale manufacturing and packaging drug substance service our service offering address small molecule produced through chemical synthesis and large molecule such antibody and protein produced through mammalian cell culture we provide development and manufacturing service for small molecule apis and the biologically active component of pharmaceutical product fisher scientific inc business continued under current good manufacturing practice cgmp condition from early development through commercial production drug product service we manufacture both small molecule and large molecule product for customer in conventional and specialized dosage form we differentiate by our breadth of dosage form and specialized capability in both oral solid and sterile dosage form we provide wide spectrum of advanced formulation production and technical service and scientific expertise and solution from the early stage of product development to regulatory approval and commercial scale production clinical trial service we provide global service for pharmaceutical and biotechnology company engaged in clinical trial including comparator sourcing specialized packaging over encapsulation multi lingual and specialized labeling and distribution for phase through phase iv clinical trial biological specimen management and biobanking service specialty pharmaceutical logistics and clinical supply chain planning and management viral vector service we provide full range of viral vector development and manufacturing service for customer developing and commercializing gene and cell therapy including process development optimization scale up analytical development and qualification of viral vector for commercial manufacturing our breadth of vector platform includes the five widely used virus type providing extensive coverage across the gene and cell therapy landscape sale and marketingwe market and sell our product and service through direct sale force customer service professional electronic commerce third party distributor and various catalog we offer our product and service through leading brand including the thermo scientific brand offer customer in research diagnostics industrial and applied market complete range of high end analytical instrument well laboratory equipment software service consumables and reagent our portfolio of product includes innovative technology for mass spectrometry chromatography elemental analysis electron microscopy molecular spectroscopy sample preparation informatics chemical research and analysis cell culture bioprocess production cellular protein and molecular biology research allergy testing drug of abuse testing therapeutic drug monitoring testing microbiology well environmental monitoring and process control the applied biosystems brand offer customer in research clinical and applied market integrated instrument system reagent and software for genetic analysis our portfolio includes innovative technology for genetic sequencing and real time digital and end point pcr that are used to determine meaningful genetic information in application such covid testing cancer diagnostics human identification testing and animal health well inherited and infectious disease the invitrogen brand offer life science customer broad range of consumables and instrument that accelerate research and ensure consistency of result our portfolio of product includes innovative solution for cellular analysis and biology flow cytometry cell culture protein expression synthetic biology molecular biology and protein biology fisher scientific is our channel brand offering customer complete portfolio of laboratory equipment and consumables chemical supply and service used in scientific research healthcare safety and education market these product are offered through an extensive network of direct sale professional segment relevant printed collateral and digital content state of the art website and supply chain management service unity lab service is our instrument and equipment service brand offering complete portfolio of service from enterprise level engagement to individual instrument and laboratory equipment regardless of the original manufacturer through our network of world class service and support personnel we provide service that are designed to help our customer improve productivity reduce cost and drive decision with better data patheon is our contract development and manufacturing brand representing the comprehensive offering of service that we provide to customer ranging from small biotech to large pharmaceutical company we support our customer development of innovative medicine including biologics gene therapy and vaccine by leveraging our expanding global network of facility we deliver high quality service at all stage of the drug lifecycle from discovery to development through clinical trial and commercial manufacturing fisher scientific inc business continued we have approximately sale personnel including highly trained technical specialist who enable to better meet the need of our more technical end user we also provide customer with product standardization and other supply chain management service to reduce procurement cost new product and research and developmentour business includes the development and introduction of new product and may include entry into new business segment we anticipate that we will continue to make significant expenditure for research and development we seek to provide continuing flow of innovative product to maintain and improve our competitive position resourcesraw materialsour management team belief that we have readily available supply of raw material for all of our significant product from various source we do not anticipate any difficulty obtaining the raw material essential to our business raw material and fuel price are subject to fluctuation due to market condition we employ many strategy including the use of alternative material to mitigate the effect of these fluctuation on our result patent license and trademarkspatents are important in many aspect of our business no particular patent or related group of patent is so important however that it loss would significantly affect our operation whole where appropriate we seek patent protection for invention and development made by our personnel that are incorporated into our product or otherwise fall within our field of interest patent right resulting from work sponsored by outside party do not always accrue exclusively to the company and may be limited by agreement or contract we protect of our technology trade secret and where appropriate we use trademark or register trademark used in connection with product we also enter into license agreement with others to grant and or receive right to patent and know seasonal influencesrevenues in the fourth quarter are historically stronger than in other quarter due to the capital spending pattern of industrial pharmaceutical and government customer sale of flu test and related diagnostic product vary quarter to quarter and year to year based on the severity and duration of each period flu season sale of allergy test vary quarter to quarter and year to year based on the severity and duration of each period airborne pollen allergen government contractsalthough the company transacts business with various government agency no government contract is of such magnitude that renegotiation of profit or termination of the contract at the election of the government agency would have material adverse effect on the company financial result competitionthe company encounter aggressive and able competition in virtually all of the market we serve of the diversity of our product and service we face many different type of competitor and competition our competitor include broad range of manufacturer and third party distributor competitive climate in many of the market we serve are characterized by changing technology and customer demand that require continuing research and development our success primarily depends on the following factor technical performance and advance in technology that result in new product and improved price performance ratio product differentiation availability and reliability the depth of our capability our reputation among customer quality provider of product and service customer service and support active research and application development program and relative price of our product and service fisher scientific inc business continued government regulationenvironmental regulationswe are subject to various law and governmental regulation concerning environmental matter and employee safety and health in the united state and other country federal environmental legislation that affect includes the toxic substance control act the resource conservation and recovery act the clean air act the clean water act the safe drinking water act and the comprehensive environmental response compensation and liability act cercla we are also subject to regulation by the occupational safety and health administration osha concerning employee safety and health matter the united state environmental protection agency usepa osha and other federal agency have the authority to promulgate regulation that have an effect on our operation in addition to these federal activity various state have been delegated certain authority under the aforementioned federal statute well authority over these matter under state law many state and local government have adopted environmental and employee safety and health law and regulation some of which are similar to federal requirement number of our operation involve the handling manufacturing use or sale of substance that are or could be classified toxic or hazardous material within the meaning of applicable law consequently some risk of environmental harm is inherent in our operation and product it is with other company engaged in similar business our expense for environmental requirement are incurred generally for ongoing compliance and historical remediation matter based on current information we believe that these compliance cost are not material for historical remediation obligation our expenditure relate primarily to the cost of permitting installing and operating and maintaining groundwater treatment system and other remedial measure our fair lawn and somerville new jersey facility entered into administrative consent order with the new jersey department of environmental protection in to maintain groundwater remediation activity at these site and are currently under the state licensed site remediation professional program the owner of the fair lawn facility we are listed potentially responsible party for remediation within an area called the fair lawn wellfields superfund site and in the company and certain other party entered into consent order with the usepa to complete remedial investigation feasibility study in the usepa issued record of decision setting forth the scope of required remediation work at the site which includes upgrading water treatment plant to address constituent such chlorinated organic compound dioxane and perfluorooctanoic acid perfluorooctane sulfonate pfoa pfos in the company and another responsible party signed proposed consent decree which the government entered in requiring the party to finance and perform the required remediation work with usepa oversight in our life technology subsidiary entered into consent decree with the usepa and other responsible party to implement groundwater remedy at the former davis landfill superfund site in smithfield rhode island we record accrual for environmental liability based on current interpretation of environmental law and regulation when it is probable that liability ha been incurred and the amount of such liability can be reasonably estimated we calculate estimate based upon several factor including report prepared by environmental specialist and management knowledge and experience with these environmental matter we include in these estimate potential cost for investigation remediation and operation and maintenance of cleanup site accrued liability for environmental matter totaled million at december these environmental liability do not include third party recovery to which we may be entitled we believe that our accrual is adequate for the environmental liability we currently expect to incur result we believe that our ultimate liability with respect to environmental matter will not have material adverse effect on our financial position result of operation or cash flow however we may be subject to remedial or compliance cost due to future event such change in existing law and regulation change in agency direction or enforcement policy development in remediation technology change in the conduct of our operation and the effect of change in accounting rule which could have material adverse effect on our financial position result of operation or cash flow other law and regulationsour operation and some of the product we offer are subject to number of complex and stringent law and regulation governing the production handling transportation and distribution of chemical drug and other similar product including the operating and security standard of the food and drug administration the drug enforcement administration the bureau of alcohol tobacco firearm and explosive and various state board of pharmacy well comparable state and foreign agency thermo fisher business also include export and import activity we are subject to pertinent law enforced by the department of commerce state and treasury in addition our logistics activity must comply with the rule and fisher scientific inc business continued regulation of the department of transportation the federal aviation administration and similar foreign agency while we believe we are in compliance in all material respect with such law and regulation any noncompliance could result in substantial fine or otherwise restrict our ability to provide competitive distribution service and thereby have an adverse effect on our financial condition to date none ha had material impact on our operation we are subject to law and regulation governing government contract and failure to address these law and regulation or comply with government contract could harm our business by leading to reduction in revenue associated with these customer we have agreement relating to the sale of our product to government entity and result we are subject to various statute and regulation that apply to company business with the government we are also subject to investigation for compliance with the regulation governing government contract failure to comply with these regulation could result in suspension of these contract criminal civil and administrative penalty or debarment human capitalthe success of thermo fisher scientific is fueled by colleague who are highly engaged and feel empowered to achieve their goal everything we do start with our mission to enable our customer to make the world healthier cleaner and safer our colleague understand the role they play in fulfilling that mission and that inspires them to bring their best to work each day our mission is not differentiator for externally but motivator for internally our culture is rooted in our value of integrity intensity innovation and involvement within this framework we strive to create safe fair and positive working environment for our colleague around the world we want our team to feel they have stake in our success voice in our direction and to be empowered to make difference for the key stakeholder we serve every year we conduct an employee involvement survey to solicit direct feedback from our colleague on we doing well and where we need to improve we then compile the feedback to measure our progress using three key index leadership involvement and inclusion in percent of our workforce completed the survey and we saw marked improvement in each index and across every survey question despite the challenge brought on by the pandemic our continued focus on enhancing our culture help position our company to be an even better place to work we are committed to building the strongest team in our industry focusing on developing and retaining our colleague while leveraging our leadership to attract new colleague to our company of our more than colleague globally of december approximately were based in the america region were in the asia pacific region and were in europe the middle east and africa emea diversity and inclusionwe recognize that the future aspiration outlined in our vision for which serf our long term roadmap will only be achievable if we have culture that value diversity and inclusion while diversity of gender and ethnicity are important and we re focused on continuously improving for diversity of background experience and viewpoint is equally vital to our long term success when those difference are welcomed and supported we create an inclusive workplace that unlocks the true benefit of diversity diversity and inclusion is not an initiative at thermo fisher scientific it woven into the fabric of our culture and our colleague are encouraged to openly share the wide range of perspective they represent we work together to create an inclusive culture where our colleague feel they belong and are empowered to contribute collaborate and innovate embracing individual difference is critical to our success for example thermo fisher wa named best place to work for lgbtq equality for the sixth consecutive year in establishing this kind of environment is critical in empowering our colleague so they can contribute their best idea and bring their true self to work each day our focus is embedded in every stage of our colleague lifecycle from recruiting to onboarding training development and longer term career planning we track our progress on our strategic objective through core set of metric that are reviewed during routine business operating mechanism including quarterly business review human resource review board review and through team dashboard that are shared each month with leader across the company this enables frequent meaningful data driven discussion across our business and function on range of factor including gender and ethnic representation this approach also ensures we consistently prioritize our opportunity to improve we understand the critical role diversity play in sustained business success and our team are empowered to ensure our workforce represents the customer we serve we are committed to ensuring our colleague have access to resource awareness training and internal network that offer support and guidance our diversity and inclusion strategy is greatly enabled by our employee resource group erg which bring together individual with similar interest to share experience learn from each other and collaborate to identify solution fisher scientific inc business continued to business challenge our erg reinforce that all colleague can make difference for our customer for each other and for our company of december we had erg globally with local erg chapter talent development our overarching goal from talent perspective is to create opportunity for our colleague to achieve their full potential and career aspiration at thermo fisher scientific we are committed to creating an exceptional colleague experience from their first day throughout their career with we focus on the entire lifecycle of colleague career from their initial recruitment to onboarding through ongoing development and training to enhance their skill so they are in the best position to deliver on their goal and achieve their career aspiration in today environment we know talent is key competitive advantage and that building the strongest team in the industry is critical to our future from our colleague referral program summer internship university relation to our graduate leadership development program we continue to build strong internal and external sourcing channel on board talent development at thermo fisher is key organizational capability we continue to make significant investment to support our colleague along every step of their career journey to help support their success our talent development framework incorporates multi faceted approach including formal and self paced training networking opportunity on the job stretch learning coaching mentoring and manager training utilizing contemporary technology solution to support the broad need of our workforce we provide multiple program at all career level from online learning for all colleague through thermo fisher university to focused training for manager at various experience level to our global leadership program for executive we also support our colleague career advancement through our tuition reimbursement program in company our size we can also actively manage our talent through rotational opportunity across our business function and geography that help our colleague gain new experience share knowledge and broaden their skill our executive and leader participate in frequent talent discussion well formal review leveraging workforce data and predictive analytics to better anticipate the talent requirement of our business based on our growth opportunity and market demand thermo fisher is dedicated to talent development to meet our evolving business need and to provide our colleague with opportunity for long and fulfilling career our colleague are passionate about our company and their role in our success and it our responsibility to help them reach their full potential total reward we offer comprehensive total reward package that we regularly evaluate and measure established benchmark to ensure it effectiveness in recruiting and retention and to position thermo fisher an employer of choice our health and wellness program provide competitive flexible program that our global colleague and their family can count on for example for colleague we offer choice of comprehensive national medical dental and vision plan wellness program including valuable health incentive opportunity and tax advantaged saving and spending account well commuter benefit employee assistance program optional group legal coverage and company paid disability accident and life insurance we also offer company paid proprietary program for cancer care called the impact program which give our colleague and their family access to personalized support and direct line of communication to expert in cancer genetics and genomics similar benefit are available in all country around the world where we operate we also invest in our colleague financial health helping them to grow and protect their saving plan for the future and share in the success of the company they are helping to build we deliver comprehensive reward including competitive base pay and also provide variety of incentive and equity program that by design directly link the impact of colleague contribution to the company overall success available informationthe company file annual quarterly and current report proxy statement and other document with the security and exchange commission sec under the exchange act the sec maintains website that contains report proxy and information statement and other information that issuer including the company file electronically with the sec the public can obtain any document that we file with the sec at www sec gov we also make available free of charge on or through our website at www thermofisher com our annual report on form quarterly report on form current report on form and if applicable amendment to those report filed or furnished pursuant to section of the exchange act soon reasonably practicable after we electronically file such material with or furnish it to the sec in addition paper copy fisher scientific inc business continued of these document may be obtained free of charge by writing to the company care of it investor relation department at our principal executive office located at third avenue waltham massachusetts information about our executive officersas of february our executive officer were nameagepresent title fiscal year first became executive officer other position heldmarc president and chief executive officer president and chief executive officer chief operating officer executive vice president mark vice president and chief operating officer executive vice president and president life science solution president and chief operating officer life technology corporation michel vice president senior vice president and president pharma service president and chief operating officer patheon managing director jll partner michael vice president and general counsel executive vice president and group general counsel luxottica group stephen vice president and chief financial officer vice president financial operation peter president and chief accounting officer corporate controller jll partner is private equity firm focused on healthcare item risk factorsset forth below are the risk that we believe are material to our investor this section contains forward looking statement should refer to the explanation of the qualification and limitation on forward looking statement in item business under the caption forward looking statement industry and economic risksour growth would suffer if the market into which we sell our product and service decline do not grow anticipated or experience cyclicality our growth depends in part on the growth of the market which we serve any decline or lower than expected growth in our served market would diminish demand for our product and service which would adversely affect our financial statement certain of our business operate in industry that may experience periodic cyclical downturn we are subject to risk associated with public health crisis and epidemic pandemic such the covid pandemic our global operation expose to risk associated with public health crisis and epidemic pandemic such covid the global spread of covid ha created significant volatility uncertainty and worldwide economic disruption resulting in an economic slowdown of potentially extended duration covid ha had an adverse impact on certain of our operation supply chain and distribution system including result of impact associated with preventive and precautionary measure that we other business and government are taking due to these impact and measure we have experienced significant and unpredictable reduction well increase in demand for certain of our product many employer in the united state and europe are continuing to require their employee to work from home or not go into their office if the pandemic continues and condition worsen we could experience decline in sale activity and customer order in certain of our business and it remains uncertain what impact these decline would have on future sale and customer order once condition begin to improve in addition to existing travel restriction country may continue to close or decline to reopen border impose prolonged quarantine and restrict travel which would significantly impact our ability to support our site and customer in those location and the ability of our employee to get to their place of work to produce product or significantly hamper our product from moving through the supply chain result covid may materially adversely affect revenue growth in certain of our business and it is uncertain how materially covid will affect our global operation generally if these impact were to persist or worsen over an extended fisher scientific inc risk factor continued period of time the extent and duration of the impact are uncertain and dependent in part on customer returning to work and economic activity ramping up the company ha mobilized to support the covid response with product and service that help diagnose the virus well assisting customer to develop potential therapeutic and vaccine used to protect from the virus our ability to continue to manufacture product is highly dependent on our ability to maintain the safety and health of our factory employee the ability of our employee to work may be significantly impacted by individual contracting or exposed to covid while we are following the requirement of governmental authority and taking preventative and protective measure to prioritize the safety of our employee these measure may not be successful and we may be required to temporarily close facility or take other measure while we are staying in close communication with our site employee customer and supplier and acting to mitigate the impact of this dynamic and evolving situation the duration and extent of the effect of covid on the company is not determinable in addition several of the company business have had an increase in revenue due to sale of product addressing diagnosis and treatment of covid while these positive impact are expected to continue into the duration and extent of future revenue from such sale are uncertain and dependent primarily on customer testing demand our business is affected by general economic condition and related uncertainty affecting market in which we operate our business is affected by general economic condition both inside and outside the if the global economy and financial market or economic condition in europe the or other key market continue to be unstable including result of the covid pandemic it could adversely affect the business result of operation and financial condition of the company and it customer distributor and supplier having the effect of reducing demand for some of our product increasing the rate of order cancellation or delay increasing the risk of excess and obsolete inventory increasing pressure on the price for our product and service causing supply interruption which could disrupt our ability to produce our product and creating longer sale cycle and greater difficulty in collecting sale proceeds economic political foreign currency and other risk associated with international sale and operation could adversely affect our result of operation international market contribute substantial portion of our revenue and we intend to continue expanding our presence in these region the exposure to fluctuation in currency exchange rate take on different form international revenue and cost are subject to the risk that fluctuation in exchange rate could adversely affect our reported revenue and profitability when translated into dollar for financial reporting purpose these fluctuation could also adversely affect the demand for product and service provided by multinational corporation our business occasionally invoice third party customer in currency other than the one in which they primarily do business the functional currency movement in the invoiced currency relative to the functional currency could adversely impact our cash flow and our result of operation our international sale grow exposure to fluctuation in currency exchange rate could have larger effect on our financial result in currency translation had favorable effect of million on revenue due to the weakening of the dollar relative to other currency in which the company sell product and service in addition many of our employee contract manufacturer supplier job function outsourcing activity and manufacturing facility are located outside the united state accordingly our future result could be harmed by variety of factor including interruption to transportation flow for delivery of part to and finished good to our customer change in specific country or region political economic or other condition change in diplomatic and trade relationship including new tariff trade protection measure import or export licensing requirement trade embargo and sanction and other trade barrier tariff imposed by the on good from other country and tariff imposed by other country on good including the tariff recently adopted by the government on various import from china and by the chinese government on certain good the impact of public health epidemic pandemic on the global economy such the covid pandemic negative consequence from change in tax law fisher scientific inc risk factor continued difficulty in staffing and managing widespread operation differing labor regulation differing protection of intellectual property unexpected change in regulatory requirement and geopolitical uncertainty or turmoil including terrorism and war for example on january the united kingdom formally withdrew from the european union or eu commonly referred to brexit and on december the and eu announced they had entered into post brexit deal on certain aspect of trade and other strategic and political issue this withdrawal ha created political and economic uncertainty particularly in the united kingdom and the eu and this uncertainty may last for year our business could be affected during this period of uncertainty and perhaps longer by the impact of the united kingdom withdrawal from the eu in addition our business could be negatively affected by new trade agreement the united kingdom and other country including the united state and by the possible imposition of trade or other regulatory barrier in the united kingdom these possible negative impact and others resulting from the united kingdom withdrawal from the eu may adversely affect our operating result and our customer business demand for some of our product depends on capital spending policy of our customer and on government funding policy our customer include pharmaceutical and chemical company laboratory university healthcare provider government agency and public and private research institution many factor including public policy spending priority available resource and product and economic cycle have significant effect on the capital spending policy of these entity spending by some of these customer fluctuates based on budget allocation and the timely passage of the annual federal budget an impasse in federal government budget decision could lead to substantial delay or reduction in federal spending business riskswe must develop new product adapt to rapid and significant technological change and respond to introduction of new product by competitor to remain competitive our growth strategy includes significant investment in and expenditure for product development we sell our product in several industry that are characterized by rapid and significant technological change frequent new product and service introduction and enhancement and evolving industry standard competitive factor include technological innovation price service and delivery breadth of product line customer support business capability and the ability to meet the special requirement of customer our competitor may adapt more quickly to new technology and change in customer requirement than we can without the timely introduction of new product service and enhancement our product and service will likely become technologically obsolete over time in which case our revenue and operating result would suffer many of our existing product and those under development are technologically innovative and require significant planning design development and testing at the technological product and manufacturing process level our customer use many of our product to develop test and manufacture their own product result we must anticipate industry trend and develop product in advance of the commercialization of our customer product if we fail to adequately predict our customer need and future activity we may invest heavily in research and development of product and service that do not lead to significant revenue it may be difficult for to implement our strategy for improving internal growth our growth depends in part on the growth of the market which we serve any decline or lower than expected growth in our served market could diminish demand for our product and service which would adversely affect our result of operation and financial condition to address this issue we are pursuing number of strategy to improve our internal growth including strengthening our presence in selected geographic market allocating research and development funding to product with higher growth prospect developing new application for our technology expanding our service offering continuing key customer initiative combining sale and marketing operation in appropriate market to compete more effectively fisher scientific inc risk factor continued finding new market for our product and continuing the development of commercial tool and infrastructure to increase and support cross selling opportunity of product and service to take advantage of our depth in product offering we may not be able to successfully implement these strategy and these strategy may not result in the expected growth of our business because we compete directly with certain of our larger customer and product supplier our result of operation could be adversely affected in the short term if these customer or supplier abruptly discontinue or significantly modify their relationship with our largest customer in the laboratory product business is also significant competitor our business may be harmed in the short term if our competitive relationship in the marketplace with certain of our large customer result in discontinuation of their purchase from in addition we manufacture product that compete directly with product that we source from third party supplier we also source competitive product from multiple supplier our business could be adversely affected in the short term if any of our large third party supplier abruptly discontinues selling product to our inability to complete any pending acquisition or to successfully integrate any new or previous acquisition could have material adverse effect on our business our business strategy includes the acquisition of technology and business that complement or augment our existing product and service certain acquisition may be difficult to complete for number of reason including the need for antitrust and or other regulatory approval any acquisition we may complete may be made at substantial premium over the fair value of the net identifiable asset of the acquired company further we may not be able to integrate acquired business successfully into our existing business make such business profitable or realize anticipated cost saving or synergy if any from these acquisition which could adversely affect our business moreover we have acquired many company and business result of these acquisition we recorded significant goodwill and indefinite lived intangible asset primarily tradenames on our balance sheet which amount to approximately billion and billion respectively of december in addition we have definite lived intangible asset totaling billion of december we ass the realizability of goodwill and indefinite lived intangible asset annually well whenever event or change in circumstance indicate that these asset may be impaired we ass the realizability of definite lived intangible asset whenever event or change in circumstance indicate that these asset may be impaired these event or circumstance would generally include operating loss or significant decline in earnings associated with the acquired business or asset our ability to realize the value of the goodwill and intangible asset will depend on the future cash flow of these business these cash flow in turn depend in part on how well we have integrated these business if we are not able to realize the value of the goodwill and intangible asset we may be required to incur material charge relating to the impairment of those asset operational risksour reliance upon sole or limited source of supply for certain material or component could cause production interruption delay and inefficiency some of our business purchase certain material from sole or limited source supplier for reason of quality assurance regulatory requirement cost effectiveness availability or uniqueness of design if these or other supplier encounter financial operating or other difficulty or if our relationship with them change we might not be able to quickly establish or qualify replacement source of supply the supply chain for our business could also be disrupted by supplier capacity constraint bankruptcy or exiting of the business for other reason decreased availability of key raw material or commodity and external event such natural disaster pandemic health issue such covid war terrorist action governmental action and legislative or regulatory change any of these factor could result in production interruption delay extended lead time and inefficiency significant disruption in or breach in security of our information technology system or violation of data privacy law could adversely affect our business part of our ongoing effort to upgrade our current information system we periodically implement new enterprise resource planning software and other software application to manage certain of our business operation we implement and add functionality problem could arise that we have not foreseen such problem could disrupt our ability to provide quote take customer order and otherwise run our business in timely manner when we upgrade or change system we may suffer interruption in service loss of data or reduced functionality in addition if our new system fail to provide accurate pricing and cost data our result of operation and cash flow could be adversely affected we also rely on our information technology system to process transmit and store electronic information including sensitive data such confidential business information and personally identifiable data relating to employee customer and other business partner and to manage or support variety of critical business process and activity such interacting with supplier selling our product and service fulfilling order and billing collecting and making payment shipping product fisher scientific inc risk factor continued providing service and support to customer tracking customer activity fulfilling contractual obligation and otherwise conducting business our system may be vulnerable to damage or interruption from natural disaster power loss telecommunication failure terrorist attack computer hacker computer virus ransomware phishing computer denial of service attack unauthorized access to customer or employee data or company trade secret and other attempt to harm our system certain of our system are not redundant and our disaster recovery planning is not sufficient for every eventuality despite any precaution we may take such problem could result in among other consequence interruption in our service which could harm our reputation and financial result any of the cyber attack breach or other disruption or damage described if significant could materially interrupt our operation delay production and shipment result in theft of our and our customer intellectual property and trade secret damage customer business partner and employee relationship and our reputation or result in defective product or service legal claim and proceeding liability and penalty under privacy law and increased cost for security and remediation each of which could adversely affect our business and financial result if we are unable to maintain reliable information technology system and appropriate control with respect to global data privacy and security requirement and prevent data breach we may suffer regulatory consequence in addition to business consequence global organization we are subject to data privacy and security law regulation and customer imposed control in numerous jurisdiction result of having access to and processing confidential personal and or sensitive data in the course of our business for example in the united state individual state regulate data breach and security requirement and multiple governmental body assert authority over aspect of the protection of personal privacy european law require to have an approved legal mechanism to transfer personal data of europe and the eu general data protection regulation imposes significantly stricter requirement in how we collect and process personal data several country such china and russia have passed law that require personal data relating to their citizen to be maintained on local server and impose additional data transfer restriction government enforcement action can be costly and interrupt the regular operation of our business and data breach or violation of data privacy law can result in fine reputational damage and civil lawsuit any of which may adversely affect our business reputation and financial statement we may incur unexpected cost from increase in fuel and raw material price which could reduce our earnings and cash flow our primary commodity exposure are for fuel petroleum based resin and steel while we may seek to minimize the impact of price increase through higher price to customer and various cost saving measure our earnings and cash flow could be adversely affected in the event these measure are insufficient to cover our cost because we rely heavily on third party package delivery service significant disruption in these service or significant increase in price may disrupt our ability to ship product increase our cost and lower our profitability we ship significant portion of our product to our customer through independent package delivery company such federal express in the and dhl in europe we also maintain small fleet of vehicle dedicated to the delivery of our product and ship our product through other carrier including national and regional trucking firm overnight carrier service and the postal service if one or more of these third party package delivery provider were to experience major work stoppage preventing our product from being delivered in timely fashion or causing to incur additional shipping cost we could not pas on to our customer our cost could increase and our relationship with certain of our customer could be adversely affected in addition if one or more of these third party package delivery provider were to increase price and we were not able to find comparable alternative or make adjustment in our delivery network our profitability could be adversely affected natural disaster public health crisis political crisis and other catastrophic event or other event outside of our control may disrupt our facility or the facility of third party on which we depend and could impact customer spending we have significant operation in california near major earthquake fault which make susceptible to earthquake risk an earthquake or other natural disaster such fire or hurricane or power shortage or outage could disrupt our operation or impair our critical system any of these disruption or other event outside of our control such strike or other labor unrest could have an adverse effect on our result of operation in addition if any of our facility including our manufacturing or warehouse facility or the facility of our supplier third party service provider or customer is affected by natural disaster such earthquake tsunami power shortage or outage flood or monsoon public health crisis such pandemic and epidemic political crisis such terrorism war political instability or other conflict or other event outside of our control such strike or other labor unrest our result of operation could be adversely affected moreover these type of event could negatively impact customer spending in the impacted region or depending upon the severity globally which could also adversely impact our operating result for example described above the covid pandemic ha impacted and could have material adverse effect on our business and result of operation fisher scientific inc risk factor continued legal quality and regulatory riskschanges in governmental regulation may reduce demand for our product or increase our expense we compete in many market in which we and our customer must comply with federal state local and international regulation such environmental health and safety and food and drug regulation we develop configure and market our product to meet customer need created by those regulation any significant change in regulation could reduce demand for our product or increase our expense for example we manufacture pharmaceutical and many of our instrument are marketed to the pharmaceutical industry for use in discovering and developing drug change in the food and drug administration regulation of the drug discovery and development process could have an adverse effect on the demand for these product we are subject to law and regulation governing government contract and failure to address these law and regulation or comply with government contract could harm our business by leading to reduction in revenue associated with these customer we have agreement relating to the sale of our product to government entity and result we are subject to various statute and regulation that apply to company doing business with the government the law governing government contract differ from the law governing private contract and government contract may contain pricing term and condition that are not applicable to private contract we are also subject to investigation for compliance with the regulation governing government contract failure to comply with these regulation could result in suspension of these contract criminal civil and administrative penalty or debarment our pharma service offering are highly complex and if we are unable to provide quality and timely offering to our customer our business could suffer our pharma service offering are highly exacting and complex due in part to strict quality and regulatory requirement our operating result in this business depend on our ability to execute and when necessary improve our quality management strategy and system and our ability to effectively train and maintain our employee base with respect to quality management failure of our quality control system could result in problem with facility operation or preparation or provision of product in each case such problem could arise for variety of reason including equipment malfunction failure to follow specific protocol and procedure problem with raw material or environmental factor and damage to or loss of manufacturing operation such problem could affect production of particular batch or series of batch of product requiring the destruction of such product or halt of facility production altogether in addition our failure to meet required quality standard may result in our failure to timely deliver product to our customer which in turn could damage our reputation for quality and service any such failure could among other thing lead to increased cost lost revenue reimbursement to customer for lost drug product registered intermediate registered starting material and active pharmaceutical ingredient other customer claim damage to and possibly termination of existing customer relationship time and expense spent investigating the cause and depending on the cause similar loss with respect to other batch or product production problem in our drug and biologic manufacturing operation could be particularly significant because the cost of raw material for such manufacturing is often high if problem in preparation or manufacture of product or failure to meet required quality standard for that product are not discovered before such product is released to the market we may be subject to adverse regulatory action including product recall product seizure injunction to halt manufacture and distribution restriction on our operation civil sanction including monetary sanction and criminal action in addition such problem or failure could subject to litigation claim including claim from our customer for reimbursement for the cost of lost or damaged active pharmaceutical ingredient the cost of which could be significant we are subject to product and other liability risk for which we may not have adequate insurance coverage we may be named defendant in product liability lawsuit which may allege that product or service we have provided from our pharma service offering have resulted or could result in an unsafe condition or injury to consumer additionally product currently or previously sold by our environmental and process instrument and radiation measurement and security instrument business include fixed and portable instrument used for chemical radiation and trace explosive detection these product are used in airport embassy cargo facility border crossing and other high threat facility for the detection and prevention of terrorist act if any of these product were to malfunction it is possible that explosive or radioactive material could fail to be detected by our product which could lead to product liability claim are also many other factor beyond our control that could lead to liability claim such the reliability and competence of the customer operator and the training of such operator any such product liability claim brought against could be significant and any adverse determination may result in liability in excess of our insurance coverage although we carry product liability insurance we can not be certain that our current insurance will be sufficient to cover these claim or that it can be maintained on acceptable term if at all we are required to comply with wide variety of law and regulation and are subject to regulation by various federal state and foreign agency we are subject to various local state federal foreign and transnational law and regulation which include the operating and security standard of the federal drug administration the fda the fisher scientific inc risk factor continued drug enforcement agency the dea various state board of pharmacy state health department the department of health and human service the dhhs the european medicine agency the ema in europe the eu member state and other comparable agency and in the future any change to such law and regulation could adversely affect in particular we are subject to law and regulation concerning current good manufacturing practice and drug safety our subsidiary may be required to register for permit and or license with and may be required to comply with the law and regulation of the dea the fda the dhhs foreign agency including the ema and other various state board of pharmacy state health department and or comparable state agency well certain accrediting body depending upon the type of operation and location of product distribution manufacturing and sale the manufacture distribution and marketing of many of our product and service including medical device and pharma service are subject to extensive ongoing regulation by the fda the dea the ema and other equivalent local state federal and non regulatory authority in addition we are subject to inspection by these regulatory authority failure by or by our customer to comply with the requirement of these regulatory authority including without limitation remediating any inspectional observation to the satisfaction of these regulatory authority could result in warning letter product recall or seizure monetary sanction injunction to halt manufacture and distribution restriction on our operation civil or criminal sanction or withdrawal of existing or denial of pending approval including those relating to product or facility in addition such failure could expose to contractual or product liability claim contractual claim from our customer including claim for reimbursement for lost or damaged active pharmaceutical ingredient well ongoing remediation and increased compliance cost any or all of which could be significant we are the sole manufacturer of number of pharmaceutical for many of our customer and negative regulatory event could impact our customer ability to provide product to their customer we are also subject to variety of federal state local and international law and regulation that govern among other thing the handling transportation and manufacture of substance that could be classified hazardous and we are required to comply with various import law and export control and economic sanction law which may affect our transaction with certain customer in certain circumstance export control and economic sanction regulation may prohibit the export of certain product service and technology in other circumstance we may be required to obtain an export license before exporting the controlled item compliance with the various import law that apply to our business can restrict our access to and increase the cost of obtaining certain product and at time can interrupt our supply of imported inventory any noncompliance by with applicable law and regulation or the failure to maintain renew or obtain necessary permit and license could result in criminal civil and administrative penalty and could have an adverse effect on our result of operation our reputation ability to do business and financial statement may be impaired by improper conduct by any of our employee agent or business partner we have internal control and compliance system to protect the company against act committed by employee agent or business that we acquire that would violate and or non law including the law governing payment to government official bribery fraud kickback and false claim pricing sale and marketing practice conflict of interest competition employment practice and workplace behavior export and import compliance money laundering and data privacy but we can not provide assurance that these control and system will prevent every such wrongful act in particular the foreign corrupt practice act the bribery act and similar anti bribery law in other jurisdiction generally prohibit company and their intermediary from making improper payment to government official for the purpose of obtaining or retaining business and we operate in many part of the world that have experienced governmental corruption to some degree any such improper action or allegation of such act could damage our reputation and subject to civil or criminal investigation in the united state and in other jurisdiction and related shareholder lawsuit could lead to substantial civil and criminal monetary and nonmonetary penalty and could cause to incur significant legal and investigatory fee in addition the government may seek to hold liable for violation committed by company which we acquire we also rely on our supplier to adhere to our supplier standard of conduct and material violation of such standard of conduct could occur that could have material effect on our business reputation and financial statement our inability to protect our intellectual property could have material adverse effect on our business in addition third party may claim that we infringe their intellectual property and we could suffer significant litigation or licensing expense result we place considerable emphasis on obtaining patent and trade secret protection for significant new technology product and process because of the length of time and expense associated with bringing new product through the development process and into the marketplace our success depends in part on our ability to develop patentable product and obtain and enforce patent protection for our product both in the united state and in other country we own numerous and foreign patent and we intend to file additional application appropriate for patent covering our product patent may not be issued for any pending or future patent application owned by or licensed to and the claim allowed under any issued patent may not be sufficiently broad to protect our technology any issued patent owned by or licensed to may be challenged invalidated or circumvented and the right under these patent may not provide with competitive advantage in fisher scientific inc risk factor continued addition competitor may design around our technology or develop competing technology intellectual property right may also be unavailable or limited in some foreign country which could make it easier for competitor to capture increased market position we could incur substantial cost to defend ourselves in suit brought against or in suit in which we may assert our patent right against others an unfavorable outcome of any such litigation could materially adversely affect our business and result of operation we also rely on trade secret and proprietary know how with which we seek to protect our product in part by confidentiality agreement with our collaborator employee and consultant these agreement may be breached and we may not have adequate remedy for any breach in addition our trade secret may otherwise become known or be independently developed by our competitor third party may assert claim against to the effect that we are infringing on their intellectual property right in the event that claim relating to intellectual property is asserted against or third party not affiliated with hold pending or issued patent that relate to our product or technology we may seek license to such intellectual property or challenge those patent however we may be unable to obtain these license on commercially reasonable term if at all and our challenge of the patent may be unsuccessful our failure to obtain the necessary license or other right could prevent the sale manufacture or distribution of our product and therefore could have material adverse effect on our business financial condition and result of operation risk relating to financial profilefluctuations in our effective tax rate may adversely affect our result of operation and cash flow global company we are subject to taxation in numerous country state and other jurisdiction in preparing our financial statement we record the amount of tax that is payable in each of the country state and other jurisdiction in which we operate our future effective tax rate however may be lower or higher than experienced in the past due to numerous factor including change in the mix of our profitability from country to country change in accounting for income tax and recently enacted and future change in tax law in jurisdiction in which we operate any of these factor could cause to experience an effective tax rate significantly different from previous period or our current expectation which could have an adverse effect on our business result of operation and cash flow our existing and future indebtedness may restrict our investment opportunity or limit our activity and negatively impact our credit rating of december we had approximately billion in outstanding indebtedness in addition we have availability to borrow under revolving credit facility that provides for up to billion of unsecured multi currency revolving credit we may also obtain additional long term debt and line of credit to meet future financing need which would have the effect of increasing our total leverage our leverage could have negative consequence including increasing our vulnerability to adverse economic and industry condition limiting our ability to obtain additional financing and limiting our ability to acquire new product and technology through strategic acquisition our ability to make scheduled payment refinance our obligation or obtain additional financing will depend on our future operating performance and on economic financial competitive and other factor beyond our control our business may not generate sufficient cash flow to meet our obligation if we are unable to service our debt refinance our existing debt or obtain additional financing we may be forced to delay strategic acquisition capital expenditure or research and development expenditure additionally the agreement governing our debt require that we maintain certain financial ratio and contain affirmative and negative covenant that restrict our activity by among other limitation limiting our ability to incur additional indebtedness merge or consolidate with other entity make investment create lien sell asset and enter into transaction with affiliate the covenant in the facility include consolidated net interest coverage ratio consolidated ebitda to consolidated net interest expense such term are defined in the facility specifically the company ha agreed that so long any lender ha any commitment under the facility any letter of credit is outstanding under the facility or any loan or other obligation is outstanding under the facility it will maintain minimum consolidated interest coverage ratio of of the last day of any fiscal quarter our ability to comply with these financial restriction and covenant is dependent on our future performance which is subject to prevailing economic condition and other factor including factor that are beyond our control such the impact of public health epidemic pandemic like covid foreign exchange rate and interest rate our failure to comply with any of these restriction or covenant may result in an event of default under the applicable debt instrument which could permit fisher scientific inc risk factor continued acceleration of the debt under that instrument and require to prepay that debt before it scheduled due date also an acceleration of the debt under certain of our debt instrument would trigger an event of default under other of our debt instrument item unresolved staff commentsnone item propertiesthe company owns and lease office engineering laboratory production and warehouse space throughout the world item legal proceedingsthere are various lawsuit and claim against the company involving product liability intellectual property employment and commercial issue see note to our consolidated financial statement commitment and contingency item mine safety disclosuresnot applicable part iiitem market for the registrant common equity related stockholder matter and issuer purchase of equity securitiesmarket price of common stockour common stock is traded on the new york stock exchange under the symbol tmo holder of common stockas of february the company had holder of record of it common stock this not include holding in street or nominee name issuer purchase of equity securitiesthere wa no share repurchase activity for the company fourth quarter of on november the board of director authorized the repurchase of up to billion of the company common stock on november the board of director replaced the existing authorization to repurchase the company common stock of which billion wa remaining with new authorization to repurchase up to billion of the company common stock early in the first quarter of the company repurchased billion of the company common stock at february billion wa available for future repurchase of the company common stock under this authorization item reservednot applicable fisher scientific inc item management discussion and analysis of financial condition and result of operationsreference is made throughout this management discussion and analysis of financial condition and result of operation to note to the consolidated financial statement which begin on page of this report management discussion and analysis of financial condition and result of operation for is included in item of the company annual report on form filed with the security and exchange commission overviewthe company develops manufacture and sell broad range of product that are sold worldwide the company expands the product line and service it offer by developing and commercializing it own technology and by making strategic acquisition of complementary business the company operation fall into four segment note life science solution analytical instrument specialty diagnostics and laboratory product and service the company mobilized in early to support the covid pandemic response with product and service that help analyze diagnose and protect from the virus however the company saw significant reduction in customer activity in several business by late march that materially adversely affected primarily the result of the analytical instrument segment and to lesser extent some business within the company other three segment the extent and duration of the negative impact continuing into are uncertain and dependent in part on the success of global effort to control the pandemic and economic activity ramping up the company belief the impacted business long term prospect remain excellent given the company attractive market served it industry leading position and proven growth strategy several of the company business have had significant increase in revenue due to sale of product and service addressing diagnosis and treatment of covid including test kit and to lesser extent product and service for therapy and vaccine development and manufacturing while these positive impact are expected to continue into the duration and extent of future revenue from such sale are uncertain and dependent primarily on customer testing demand recent acquisition and divestiturethe company strategy is to augment internal growth at existing business with complementary acquisition the company principal recent acquisition and divestiture are described below on april the company acquired within the laboratory product and service segment brammer bio for approximately billion in cash brammer bio is leading viral vector contract development and manufacturing organization for gene and cell therapy the acquisition expanded the segment contract manufacturing capability brammer bio reported revenue of approximately million in on june the company sold it anatomical pathology business to phc holding corporation for billion net of cash divested the business wa part of the specialty diagnostics segment revenue in through the date of sale and the full year of the business sold were approximately million and million respectively net of retained sale through the company healthcare market and research and safety market channel business overview of result of operation and liquidity dollar in million science solution analytical specialty laboratory product and elimination sale in were billion an increase of billion from sale increased million due to acquisition net of divestiture the favorable effect of currency translation resulted in an increase in revenue of million in fisher scientific inc management discussion and analysis of financial condition and result of operationsoverview of result of operation and liquidity continued aside from the effect of acquisition divestiture and currency translation revenue increased billion primarily due to increased demand sale of product that address covid testing and treatment totaled billion in and were offset in part by lower revenue in the remainder of the business during the first half of sale were particularly strong in diagnostic and healthcare market due to demand for product supporting customer diagnosing the covid virus offset in part by lower sale of other product due to pandemic related impact on customer activity sale were also strong to customer in pharma and biotech market where demand wa strong for product and service and pandemic related demand for therapy and vaccine also contributed to growth sale to customer in industrial market decreased primarily due to lower demand from weakened economic condition related to covid sale to these customer returned to positive growth in the fourth quarter of sale to academic and government customer decreased due primarily to closure of academic lab during the global pandemic sale to these customer returned to positive growth in the third quarter of sale growth wa particularly strong in north america and europe and to lesser extent in the asia pacific region in total company operating income and operating income margin were billion and respectively compared with billion and respectively in the increase in operating income wa primarily due to profit on higher sale and to lesser extent sale mix offset in part by gain on the sale of the anatomical pathology business included in the period and strategic growth investment in the company reference to strategic growth investment generally refer to targeted spending for enhancing commercial capability including expansion of geographic sale reach and commerce platform marketing initiative expanded service and operational infrastructure focused research and development project and other expenditure to enhance the customer experience well incentive compensation and recognition for employee the company reference throughout this discussion to productivity improvement generally refer to improved cost efficiency from it practical process improvement ppi business system reduced cost resulting from global sourcing initiative lower cost structure following restructuring action including headcount reduction and consolidation of facility and low cost region manufacturing productivity improvement are calculated net of inflationary cost increase the company recorded provision for income tax of million in effective tax rate of in the company implemented foreign tax credit planning in sweden which resulted in million of foreign tax credit with no related incremental income tax expense and also recorded net income tax benefit of million from domestication transaction involving the transfer of non subsidiary to the million income tax benefit related to foreign exchange loss for tax purpose on certain intercompany financing arrangement and million tax benefit from tax audit settlement the company recorded provision for income tax of million in effective tax rate of including million related to the gain on the sale of the anatomical pathology business in the company recorded million income tax benefit related to foreign exchange loss for tax purpose on certain intercompany financing arrangement implemented foreign tax credit planning in sweden which resulted in million of foreign tax credit with no related incremental income tax expense and recorded million income tax benefit related to the deferred tax implication of intra entity transaction which included tax benefit to release valuation allowance against net operating loss previously determined to be unrealizable the effective tax rate in both and wa also affected by relatively significant earnings in lower tax jurisdiction due primarily to the non deductibility of intangible asset amortization for tax purpose the company cash payment for income tax were higher than it income tax expense for financial reporting purpose and totaled billion and billion in and respectively the company expects it effective tax rate in will be between and based on currently forecasted rate of profitability in the country in which the company conduct business and expected generation of foreign tax credit the effective tax rate can vary significantly from period to period result of discrete income tax factor and event net income increased to billion in from billion in principally due to the increase in operating income in discussed above offset in part by the increase in the income tax provision during the company cash flow from operation totaled billion compared with billion for the increase primarily resulted from higher cash provided by income and to lesser extent lower investment in working capital in of december the company short term debt totaled billion substantially all of which wa redeemed in january the company ha revolving credit facility with bank group that provides up to billion of unsecured multi currency revolving credit note if the company borrows under this facility it intends to leave undrawn an amount fisher scientific inc management discussion and analysis of financial condition and result of operationsoverview of result of operation and liquidity continued equivalent to outstanding commercial paper to provide source of fund in the event that commercial paper market are not available of december no borrowing were outstanding under the company revolving credit facility although available capacity wa reduced by approximately million result of outstanding letter of credit the company belief that it existing cash and cash equivalent of billion of december and it future cash flow from operation together with available borrowing capacity under it revolving credit agreement will be sufficient to meet the cash requirement of it existing business for the foreseeable future including at least the next month critical accounting policy and estimatesthe company discussion and analysis of it financial condition and result of operation is based upon it financial statement which have been prepared in accordance with accounting principle generally accepted in the united state of america the preparation of these financial statement requires management to make estimate and assumption that affect the reported amount of asset liability revenue and expense and related disclosure of contingent liability on an on going basis management evaluates it estimate including those related to intangible asset and goodwill income tax and contingency and litigation management belief the most complex and sensitive judgment because of their significance to the consolidated financial statement result primarily from the need to make estimate about the effect of matter that are inherently uncertain management base it estimate on historical experience current market and economic condition and other assumption that management belief are reasonable the result of these estimate form the basis for judgment about the carrying value of asset and liability where the value are not readily apparent from other source actual result may differ from these estimate under different assumption or condition the company belief the following represent it critical accounting policy and estimate used in the preparation of it financial statement intangible asset and goodwillthe company us assumption and estimate in determining the fair value of asset acquired and liability assumed in business combination the determination of the fair value of intangible asset which represent significant portion of the purchase price in many of the company acquisition requires the use of significant judgment with regard to the fair value and ii whether such intangible are amortizable or non amortizable and if the former the period and the method by which the intangible asset will be amortized the company estimate the fair value of acquisition related intangible asset principally based on projection of cash flow that will arise from identifiable intangible asset of acquired business the projected cash flow are discounted to determine the present value of the asset at the date of acquisition definite lived intangible asset totaled billion at december the company review definite lived intangible asset for impairment when indication of potential impairment exists such significant reduction in cash flow associated with the asset actual cash flow arising from particular intangible asset could vary from projected cash flow which could imply different carrying value from those established at the date of acquisition and which could result in impairment of such asset the company evaluates goodwill and indefinite lived intangible asset for impairment annually and when event occur or circumstance change that would more likely than not reduce the fair value of the asset below it carrying amount event or circumstance that might require an interim evaluation include unexpected adverse business condition economic factor unanticipated technological change or competitive activity loss of key personnel and act by government and court goodwill and indefinite lived intangible asset totaled billion and billion respectively at december estimate of discounted future cash flow require assumption related to revenue and operating income growth rate discount rate and other factor for the goodwill impairment test the company considers peer revenue and earnings trading multiple from company that have operational and financial characteristic that are similar to the respective reporting unit and ii estimated weighted average cost of capital different assumption from those made in the company analysis could materially affect projected cash flow and the company evaluation of goodwill and indefinite lived intangible asset for impairment the company performed the quantitative goodwill impairment test for all of it reporting unit and indefinite lived intangible asset indication of fair value based on projection of profitability and on peer revenue and earnings trading multiple were sufficient to conclude that no impairment of goodwill or indefinite lived intangible asset existed at the end of the tenth fiscal month of the date of the company annual impairment testing there can be no assurance however that an economic downturn will not materially adversely affect peer trading multiple and the fisher scientific inc management discussion and analysis of financial condition and result of operationscritical accounting policy and estimate continued company business such that they do not achieve their forecasted profitability and these asset become impaired should the fair value of the company goodwill or indefinite lived intangible asset decline because of reduced operating performance market decline or other indicator of impairment or result of change in the discount rate charge for impairment may be necessary income taxesin the ordinary course of business there is inherent uncertainty in quantifying the company income tax position the company ass income tax position and record tax benefit for all year subject to examination based upon management evaluation of the fact circumstance and information available at the reporting date for those tax position where it is more likely than not that tax benefit will be sustained the company ha recorded the largest amount of tax benefit with greater than percent likelihood of being realized upon ultimate settlement with taxing authority that ha full knowledge of all relevant information for those income tax position where it is not more likely than not that tax benefit will be sustained no tax benefit ha been recognized in the financial statement should tax return position that the company expects are sustainable not be sustained upon audit the company could be required to record an incremental tax provision for such tax the company liability for these unrecognized tax benefit totaled billion at december the company operates in numerous country under many legal form and result is subject to the jurisdiction of numerous domestic and non tax authority well to tax agreement and treaty among these government determination of taxable income in any jurisdiction requires the company to interpret the related tax law and regulation and the use of estimate and assumption regarding significant future event such the amount timing and character of deduction permissible revenue recognition method under the tax law and the source and character of income and tax credit change in tax law regulation agreement and treaty currency exchange restriction or the company level of operation or profitability in each taxing jurisdiction could have an impact upon the amount of current and deferred tax balance and hence the company net income the company estimate the degree to which tax asset will result in benefit after consideration of all positive and negative evidence and provides valuation allowance for tax asset that it belief will more likely than not go unused in situation in which the company ha been able to determine that it deferred tax asset will be realized that determination generally relies on future reversal of taxable temporary difference and expected future taxable income if it becomes more likely than not that tax asset will be used the company revers the related valuation allowance any such reversal are recorded reduction of the company tax provision the company tax valuation allowance totaled million at december should the company actual future taxable income by tax jurisdiction vary from estimate additional allowance or reversal thereof may be necessary the company ha not provided state income tax or additional non tax on certain of it non subsidiary undistributed earnings such amount are intended to be reinvested outside the united state indefinitely in the respective jurisdiction based on specific business plan and tax strategy these business plan and tax strategy consider short term and long term forecast and budget of the parent and non subsidiary working capital and other need in location where earnings are generated the company past practice regarding non subsidiary dividend source of financing by the parent such issuing debt or equity and us of cash by the parent that are more discretionary in nature such business combination and share repurchase program however should the company change it business plan and tax strategy in the future and decide to repatriate portion of these earnings to one of it subsidiary including cash maintained by these non subsidiary the company would recognize additional tax liability it is not practicable to estimate the amount of additional state income tax and non tax liability that the company would incur the company intent is to only make distribution from non subsidiary in the future when they can be made at no net tax cost contingency and litigationthe company record accrual for various contingency including legal proceeding environmental worker compensation product general and auto liability and other claim that arise in the normal course of business the accrual are based on management judgment historical claim experience the probability of loss and where applicable the consideration of opinion of internal and or external legal counsel and actuarial estimate accrual of acquired business including product liability and environmental accrual are initially recorded at fair value and discounted to their net present value additionally the company record receivables from third party insurer when recovery ha been determined to be probable fisher scientific inc management discussion and analysis of financial condition and result of operationsresults of compared with in million divestituresoperationsrevenues life science solution analytical specialty laboratory product and elimination consolidated revenue sale in were billion an increase of billion from sale increased million due to acquisition net of divestiture the favorable effect of currency translation resulted in an increase in revenue of million in aside from the effect of acquisition and currency translation revenue increased billion primarily due to increased demand sale of product that address covid testing and treatment totaled billion in and were offset in part by lower revenue in the remainder of the business during the first half of sale were particularly strong in diagnostic and healthcare market due to demand for product supporting customer diagnosing the covid virus offset in part by lower sale of other product due to pandemic related impact on customer activity sale were also strong to customer in pharma and biotech market where demand wa strong for product and service and pandemic related demand for therapy and vaccine also contributed to growth sale to customer in industrial market decreased primarily due to lower demand from weakened economic condition related to covid sale to these customer returned to positive growth in the fourth quarter of sale to academic and government customer decreased due primarily to closure of academic lab during the global pandemic sale to these customer returned to positive growth in the third quarter of sale growth wa particularly strong in north america and europe and to lesser extent in the asia pacific region in total company operating income and operating income margin were billion and respectively compared with billion and respectively in the increase in operating income wa primarily due to profit on higher sale and to lesser extent sale mix offset in part by gain on the sale of the anatomical pathology business included in the period and strategic growth investment in in the company recorded restructuring and other cost net of million note in the company recorded restructuring and other income net of million including million of net gain on the sale of business principally the anatomical pathology business note the restructuring project for which charge were incurred in are expected to result in annual cost saving of approximately million beginning in part in and to greater extent in the restructuring action for which charge were incurred in resulted in annual cost saving of approximately million beginning in part in and to greater extent in segment resultsthe company management evaluates segment operating performance using operating income before certain charge credit to cost of revenue and selling general and administrative expense principally associated with acquisition related activity restructuring and other cost income including cost arising from facility consolidation such severance and abandoned lease expense and gain and loss from the sale of real estate and product line and amortization of acquisition related intangible asset the company us this measure because it help management understand and evaluate the segment core operating result and facilitate comparison of performance for determining compensation note accordingly the following segment data is reported on this basis fisher scientific inc management discussion and analysis of financial condition and result of operationsresults of operation continued dollar in million science solution analytical specialty laboratory product and elimination consolidated revenue segment incomelife science solution analytical specialty laboratory product and subtotal reportable cost of revenue charge selling general and administrative charge restructuring and other cost income net amortization of acquisition related intangible asset consolidated operating income reportable segment income consolidated operating income income from the company reportable segment increased to billion in due primarily to profit on higher sale and to lesser extent sale mix offset in part by strategic growth investment life science solution dollar in million operating income ptsales in the life science solution segment increased billion to billion in sale increased billion due to higher revenue at existing business the favorable effect of currency translation resulted in an increase in revenue of million the increase in revenue at existing business wa primarily driven by demand for testing to diagnose covid with higher sale of genetic science product and to lesser extent bioscience product sale also grew due to higher demand for bioproduction product operating income margin wa in compared to in the increase resulted primarily from profit on higher sale and to lesser extent sale mix offset in part by strategic growth investment analytical instrument dollar in million operating income fisher scientific inc management discussion and analysis of financial condition and result of operationsresults of operation continued sale in the analytical instrument segment decreased million to billion in sale decreased million due to lower revenue at existing business the favorable effect of currency translation resulted in an increase in revenue of million the decrease in revenue at existing business wa primarily the result of reduced demand from industrial customer following business slowing and closure due to covid and lower sale to academic customer due to pandemic related closure the segment returned to positive growth in the fourth quarter of operating income margin wa in compared to in the decrease wa primarily due to sale mix the decrease in sale million charge related to long term supply contract discussed in note and to lesser extent strategic growth investment offset in part by productivity improvement specialty diagnostics dollar in million operating income ptsales in the specialty diagnostics segment increased billion to billion in sale increased billion due to higher revenue at existing business the favorable effect of currency translation resulted in an increase in revenue of million and the divestiture of the anatomical pathology business in june decreased revenue by million the increase in revenue at existing business wa due to higher demand primarily driven by product addressing treatment of covid with particular strength in sale of product sold through the segment healthcare market channel business and to lesser extent microbiology and clinical diagnostics product these increase were offset in part by lower sale in some of the segment business due to pandemic related reduction in demand operating income margin wa in and in the increase wa primarily due to profit on higher sale offset in part by sale mix and to lesser extent strategic growth investment laboratory product and service dollar in million operating income ptsales in the laboratory product and service segment increased billion to billion in sale increased billion due to higher revenue at existing business and million due to acquisition the favorable effect of currency translation resulted in an increase in revenue of million the increase in revenue at existing business wa primarily due to increased demand for product sold through it research and safety market channel business and to lesser extent service offering of the segment pharma service business the increase in demand wa driven by pandemic response well the segment other product and service operating income margin wa in and in the decrease wa primarily due to sale mix and strategic growth investment offset in part by profit on higher sale and to lesser extent productivity improvement other expense netin the company recorded million of financing cost for terminated acquisition primarily for amortization of loan commitment fee and entering into currency hedging contract in the company recorded million of loss on the early extinguishment of debt offset in part by million of net gain on investment the investment gain include million gain on the sale of joint venture for net proceeds of million in the first quarter of the company recorded approximately million of loss on the early extinguishment of debt note provision for income taxesthe company recorded provision for income tax of million in effective tax rate of in the company implemented foreign tax credit planning in sweden which resulted in million of foreign tax credit with no related incremental income tax expense and also recorded net income tax benefit of million from domestication fisher scientific inc management discussion and analysis of financial condition and result of operationsresults of operation continued transaction involving the transfer of non subsidiary to the million income tax benefit related to foreign exchange loss for tax purpose on certain intercompany financing arrangement and million tax benefit from tax audit settlement the company recorded provision for income tax of million in effective tax rate of including million related to the gain on the sale of the anatomical pathology business in the company recorded million income tax benefit related to foreign exchange loss for tax purpose on certain intercompany financing arrangement implemented foreign tax credit planning in sweden which resulted in million of foreign tax credit with no related incremental income tax expense and recorded million income tax benefit related to the deferred tax implication of intra entity transaction which included tax benefit to release valuation allowance against net operating loss previously determined to be unrealizable the effective tax rate in both and wa also affected by relatively significant earnings in lower tax jurisdiction due primarily to the non deductibility of intangible asset amortization for tax purpose the company cash payment for income tax were higher than it income tax expense for financial reporting purpose and totaled billion and billion in and respectively the company expects it effective tax rate in will be between and based on currently forecasted rate of profitability in the country in which the company conduct business and expected generation of foreign tax credit the effective tax rate can vary significantly from period to period result of discrete income tax factor and event the company ha operation and taxable presence in approximately country outside the some of these country have lower tax rate than the the company ability to obtain benefit from lower tax rate outside the is dependent on it relative level of income in country outside the and on the statutory tax rate in those country based on the dispersion of the company non income tax provision among many country the company belief that change in the statutory tax rate in any individual country is not likely to materially affect the company income tax provision or net income aside from any resulting one time adjustment to the company deferred tax balance to reflect new rate recent accounting pronouncementsa description of recently issued accounting standard is included under the heading recent accounting pronouncement in note contingent liabilitiesthe company is contingently liable with respect to certain legal proceeding and related matter an unfavorable outcome that differs materially from current accrual estimate if any for one or more of the matter described under the heading product liability worker compensation and other personal injury matter in note could have material adverse effect on the company financial position well it result of operation and cash flow liquidity and capital resourcesconsolidated working capital current asset le current liability wa billion at december compared with billion at december included in working capital were cash and cash equivalent of billion at december and billion at december the increase in cash wa primarily due to the issuance of long term senior note in march and april and higher cash flow from operation in cash provided by operating activity wa billion during cash provided by income wa offset in part by investment in working capital increase in account receivable and inventory used cash of billion and million respectively primarily to support growth in sale change in other asset and liability provided cash of billion primarily due to the timing of incentive compensation payment and to lesser extent customer billing cash payment for income tax increased to billion during compared with billion in during the company investing activity used billion of cash principally for the purchase of property plant and equipment in january and february the company completed acquisition for approximately million in cash plus contingent consideration and entered an agreement to acquire another business for million in cash plus contingent consideration note fisher scientific inc management discussion and analysis of financial condition and result of operationsliquidity and capital resource continued the company financing activity provided million of cash during issuance of senior note provided cash of billion repayment of senior note used cash of million the company financing activity also included the repurchase of billion of the company common stock and the payment of million in cash dividend offset in part by million of net proceeds from employee stock option exercise on november the board of director authorized the repurchase of up to billion of the company common stock on november the board of director replaced the existing authorization to repurchase the company common stock of which billion wa remaining with new authorization to repurchase up to billion of the company common stock early in the first quarter of the company repurchased billion of the company common stock at february authorization remained for billion of future repurchase of the company common stock of december the company short term debt totaled billion substantially all of which wa redeemed in january the company ha revolving credit facility with bank group that provides up to billion of unsecured multi currency revolving credit note if the company borrows under this facility it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide source of fund in the event that commercial paper market are not available of december no borrowing were outstanding under the company revolving credit facility although available capacity wa reduced by approximately million result of outstanding letter of credit approximately half of the company cash balance and cash flow from operation are from outside the the company us it non cash for need outside of the including acquisition and repayment of acquisition related intercompany debt to the in addition the company also transfer cash to the using non taxable return of capital well dividend where the related dividend received deduction or foreign tax credit equal any tax cost arising from the dividend result of using such mean of transferring cash to the the company doe not expect any material adverse liquidity effect from it significant non cash balance for the foreseeable future the company belief that it existing cash and cash equivalent of billion of december and it future cash flow from operation together with available borrowing capacity under it revolving credit agreement will be sufficient to meet the cash requirement of it existing business for the foreseeable future including at least the next month the company expects that for expenditure for property plant and equipment net of disposal will be between and billion in addition to the obligation on the balance sheet at december which include debt note unrecognized tax benefit note operating lease note and pension obligation note the company ha entered into unconditional purchase obligation in the ordinary course of business that include agreement to purchase good service or fixed asset and to pay royalty note cash provided by operating activity wa billion during cash provided by income wa offset in part by increased investment in working capital increase in account receivable and inventory used cash of million and million respectively primarily to support growth in sale change in other asset and liability used cash of million primarily due to the timing of customer billing and tax refund offset in part by advanced payment from customer cash payment for income tax increased to million during compared with million in during the company investing activity used billion of cash acquisition used cash of billion proceeds from the sale of the anatomical pathology business provided billion the company investing activity also included the purchase of million of property plant and equipment the company financing activity used billion of cash during repayment of senior note used cash of billion new long term borrowing provided cash of billion net decrease in commercial paper obligation used cash of million the company financing activity also included the repurchase of billion of the company common stock and the payment of million in cash dividend offset in part by million of net proceeds from employee stock option exercise fisher scientific inc item quantitative and qualitative disclosure about market riskthe company is exposed to market risk from change in interest rate and currency exchange rate which could affect it future result of operation and financial condition the company manages it exposure to these risk through it regular operating and financing activity the company ha periodically hedged interest rate risk of fixed rate instrument with offsetting interest rate swap additionally the company us short term forward and option contract primarily to hedge certain balance sheet and operational exposure resulting from change in currency exchange rate such exposure result from purchase sale cash and intercompany loan that are denominated in currency other than the functional currency of the respective operation the currency exchange contract principally hedge transaction denominated in swiss franc euro british pound sterling canadian dollar hong kong dollar japanese yen and czech koruna income and loss arising from these derivative contract are recognized offset to loss and income resulting from the underlying exposure being hedged the company doe not enter into speculative derivative agreement interest ratesthe company is exposed to change in interest rate while conducting normal business operation result of ongoing investing and financing activity which affect the company debt well cash and cash equivalent of december the company debt portfolio wa comprised primarily of fixed rate borrowing the fair market value of the company fixed interest rate debt is subject to interest rate risk generally the fair market value of fixed interest rate debt will increase interest rate fall and decrease interest rate rise the total estimated fair value of the company debt at december wa billion note fair value were determined from available market price using current interest rate and term to maturity if interest rate were to decrease by basis point the fair value of the company debt at december would increase by approximately billion if interest rate were to increase by basis point the fair value of the company debt at december would decrease by approximately billion in addition interest rate change would result in change in the company interest expense due to variable rate debt instrument including swap arrangement in basis point increase in interest rate on the swap arrangement and variable rate debt would have increased the company annual pre tax interest expense by approximately million currency exchange ratesthe company view it investment in international subsidiary with functional currency other than the dollar permanent the company investment in international subsidiary is sensitive to fluctuation in currency exchange rate the functional currency of the company international subsidiary are principally denominated in euro british pound sterling swedish kronor canadian dollar swiss franc norwegian krone and danish krone the effect of change in the period ending currency exchange rate on the company net investment in international subsidiary is reflected in the accumulated other comprehensive item component of shareholder equity the company also us foreign currency denominated debt to partially hedge it net investment in foreign operation against adverse movement in exchange rate depreciation in year end functional currency relative to the dollar would result in reduction of shareholder equity of approximately billion the fair value of forward currency exchange contract is sensitive to change in currency exchange rate the fair value of forward currency exchange contract is the estimated amount that the company would pay or receive upon termination of the contract taking into account the change in currency exchange rate depreciation in year end non functional currency exchange rate related to the company contract would result in an additional unrealized loss on forward currency exchange contract of million appreciation in year end non functional currency exchange rate related to the company contract would result in an unrealized gain on forward currency exchange contract of million the unrealized gain or loss on forward currency exchange contract resulting from change in currency exchange rate are expected to approximately offset loss or gain on the exposure being hedged certain of the company cash and cash equivalent are denominated in currency other than the functional currency of the depositor and are sensitive to change in currency exchange rate depreciation in the related year end non functional currency exchange rate applied to such cash balance would result in negative impact of million on the company net income fisher scientific inc item financial statement and supplementary datathis data is submitted separate section to this report see item exhibit and financial statement schedule item change in and disagreement with accountant on accounting and financial disclosurenot applicable item control and proceduresmanagement evaluation of disclosure control and proceduresthe company management with the participation of the company chief executive officer and chief financial officer ha evaluated the effectiveness of the company disclosure control and procedure such term is defined in rule and under the exchange act of the end of the period covered by this report based on such evaluation the company chief executive officer and chief financial officer concluded that of the end of such period the company disclosure control and procedure were effective at the reasonable assurance level change in internal control over financial reportingthere have been no change in the company internal control over financial reporting defined in exchange act rule and during the fiscal quarter ended december that have materially affected or are reasonably likely to materially affect the company internal control over financial reporting management annual report on internal control over financial reportingthe company management including the company chief executive officer and chief financial officer is responsible for establishing and maintaining adequate internal control over financial reporting defined in exchange act rule and for the company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle the company management conducted an assessment of the effectiveness of the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission coso based on this assessment the company management concluded that of december the company internal control over financial reporting wa effective the company independent registered public accounting firm pricewaterhousecoopers llp ha audited the effectiveness of the company internal control over financial reporting of december stated in their report that appears on page of this annual report on form item other informationnot applicable fisher scientific inc part iiiitem director executive officer and corporate governancethe information with respect to director required by this item will be contained in our definitive proxy statement to be filed with the sec not later than day after the close of business of the fiscal year definitive proxy statement and is incorporated in this report by reference the information with respect to executive officer required by this item is included in item of part of this report the other information required by this item will be contained in our definitive proxy statement and is incorporated in this report by reference item executive compensationthe information required by this item will be contained in our definitive proxy statement and is incorporated in this report by reference item security ownership of certain beneficial owner and management and related stockholder mattersthe information required by this item will be contained in our definitive proxy statement and is incorporated in this report by reference item certain relationship and related transaction and director independencethe information required by this item will be contained in our definitive proxy statement and is incorporated in this report by reference item principal accountant fee and servicesthe information required by this item will be contained in our definitive proxy statement and is incorporated in this report by reference part ivitem exhibit and financial statement schedule the following document are filed part of this report consolidated financial statement see index on page of this report report of independent registered public accounting firmconsolidated balance sheetconsolidated statement of incomeconsolidated statement of comprehensive incomeconsolidated statement of cash flowsconsolidated statement of shareholder equitynotes to consolidated financial statement all schedule are omitted because they are not applicable or not required or because the required information is included either in the consolidated financial statement or in the note thereto exhibitssee the exhibit index on page item form summarynone to the requirement of section or of the security exchange act of the registrant ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized date february fisher scientific inc by marc caspermarc casperchairman president and chief executive officerpursuant to the requirement of the security exchange act of this report ha been signed below by the following person on behalf of the registrant and in the capacity indicated of february by marc casperby thomas lynchmarc casperthomas lynchchairman president and chief executive officerlead director principal executive officer by stephen williamsonby jim manzistephen williamsonjim manzisenior vice president and chief financial officerdirector principal financial officer by peter hornstraby james mullenpeter hornstrajames mullenvice president and chief accounting officerdirector principal accounting officer by nelson chaiby lars srensennelson chailars srensendirectordirectorby martin harrisby debora sparc martin harrisdebora spardirectordirectorby tyler jacksby scott sperlingtyler jacksscott sperlingdirectordirectorby alexandra keithby dion weislerr alexandra keithdion weislerdirectordirectorby judy lewentjudy fisher scientific inc exhibit indexexhibit numberdescription of and restated certificate of incorporation of the registrant filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference to thermo fisher scientific inc third amended and restated certificate of incorporation filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference of elimination of the series junior participating preferred stock of the company dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference and restated by law of the registrant amended and effective of february filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference the registrant agrees pursuant to item iii of regulation to furnish to the commission upon request copy of each instrument with respect to long term debt of the registrant or it consolidated subsidiary dated of november between the company and the bank of new york mellon trust company filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference supplemental indenture dated of december between the company and the bank of new york mellon trust company filed exhibit to the registrant current report on form filed december file no and incorporated in this document by reference supplemental indenture dated of november among the company the bank of new york mellon trust company trustee and the bank of new york mellon london branch paying agent filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference supplemental indenture dated of july among the company the bank of new york mellon trust company trustee and the bank of new york mellon london branch paying agent filed exhibit to the registrant current report on form filed july file no and incorporated in this document by reference supplemental indenture dated of december between the company and the bank of new york mellon trust company filed exhibit to the registrant current report on form filed december file no and incorporated in this document by reference supplemental indenture dated of april between the company and the bank of new york mellon trust company filed exhibit to the registrant current report on form filed april file no and incorporated in this document by reference supplemental indenture dated of september between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed september file no and incorporated in this document by reference supplemental indenture dated of september between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed september file no and incorporated in this document by reference supplemental indenture dated of march between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed march file no and incorporated in this document by reference supplemental indenture dated of july between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed july file no and incorporated in this document by reference supplemental indenture dated of august between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed august file no and incorporated in this document by reference supplemental indenture dated of september between the company issuer and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed september file no and incorporated in this document by reference supplemental indenture dated of october between the company issuer and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed october file no and incorporated in this document by reference supplemental indenture dated of march between the company issuer and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed march file no and incorporated in this document by reference first supplemental indenture dated of april between the company issuer and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed april file no and incorporated in this document by reference fisher scientific inc exhibit indexexhibit numberdescription of of the registrant security filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference fisher scientific inc deferred compensation plan for director of the registrant amended and restated on september filed exhibit to the registrant quarterly report on form for the quarter ended september file no and incorporated in this document by reference electron corporation deferred compensation plan effective november filed exhibit to the registrant annual report on form for the fiscal year ended december file no and incorporated in this document by reference of amended and restated indemnification agreement between the registrant and it director and officer filed exhibit to the registrant registration statement on form reg no and incorporated in this document by reference of thermo fisher scientific inc annual director compensation filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of annual cash incentive plan matter set forth in item to the registrant current report on form filed february file no under the heading compensatory arrangement of certain officer and incorporated in this document by reference of noncompetition agreement between the registrant and certain key employee and executive officer filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference plan for non employee director of fisher scientific international inc filed exhibit to fisher scientific international inc annual report on form for the year ended december file no and incorporated in this document by reference amendment to the fisher scientific international inc retirement plan for non employee director filed exhibit to fisher scientific international inc quarterly report on form for the quarter ended march file no and incorporated in this document by reference to retirement plan for non employee director of fisher scientific international inc filed exhibit to fisher scientific international inc current report on form filed march file no and incorporated in this document by reference fisher scientific inc amended and restated deferred compensation plan effective january filed exhibit to the registrant quarterly report on form for the quarter ended june file no and incorporated in this document by reference restatement of executive severance agreement between marc casper and the registrant dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference change in control retention agreement between marc casper and the registrant dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference agreement between marc casper and the registrant dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference no to restatement of executive severance agreement dated february between the registrant and marc casper filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference no to restatement of executive severance agreement dated november between the registrant and marc casper filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference no to executive change in control retention agreement dated november between marc casper and the registrant filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference no to executive change in control retention agreement dated march between marc casper and the registrant filed exhibit to the registrant quarterly report on form for the quarter ended march file no and incorporated in this document by reference of executive change in control retention agreement for officer other than marc casper filed exhibit to the registrant quarterly report on form for the quarter ended march file no and incorporated in this document by reference of thermo fisher scientific inc restricted stock unit agreement for director filed exhibit to the registrant quarterly report on form for the quarter ended april file no and incorporated in this document by reference fisher scientific inc exhibit indexexhibit numberdescription of of thermo fisher scientific inc performance restricted stock unit agreement filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference of thermo fisher scientific inc restricted stock unit agreement filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference of performance restricted stock unit agreement between thermo fisher scientific inc and marc casper filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference of restricted stock unit agreement between thermo fisher scientific inc and marc casper filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference of stock option agreement between thermo fisher scientific inc and marc casper filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference fisher scientific inc stock incentive plan filed exhibit to the registrant current report on form filed may file no and incorporated in this document by reference executive retirement plan effective of december amended and restated of august filed exhibit to applera corporation quarterly report on form for the quarter ended september file no and incorporated in this document by reference to supplemental executive retirement plan effective of january filed exhibit to life technology corporation current report on form filed december file no and incorporated in this document by reference agreement between the registrant and mark stevenson dated september filed exhibit to the registrant quarterly report on form for the quarter ended september file no and incorporated in this document by reference of thermo fisher scientific inc stock option agreement for officer filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference omnibus incentive plan filed exhibit to the current report on form filed by patheon on july file no and incorporated in this document by reference to patheon omnibus incentive plan dated march filed exhibit to the registrant registration statement on form filed august file no and incorporated in this document by reference to patheon omnibus incentive plan dated august filed exhibit to the registrant registration statement on form filed august file no and incorporated in this document by reference agreement dated december among thermo fisher scientific inc certain subsidiary of thermo fisher scientific inc from time to time party thereto bank of america administrative agent and each lender from time to time party thereto filed exhibit to the registrant current report on form filed december file no and incorporated in this document by reference of performance restricted stock unit agreement effective february filed exhibit to the registrant quarterly report on form for the quarter ended march file no and incorporated in this document by reference of performance restricted stock unit agreement for marc casper effective february filed exhibit to the registrant quarterly report on form for the quarter ended march file no and incorporated in this document by reference agreement between the registrant and michel lagarde dated august filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference agreement under the patheon omnibus incentive plan between patheon and michel lagarde dated july filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference agreement under the patheon omnibus incentive plan between patheon and michel lagarde dated march filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference fisher scientific inc executive severance policy filed exhibit to the registrant quarterly report on form for the quarter ended june file no and incorporated in this document by reference fisher scientific inc exhibit indexexhibit numberdescription of of noncompetition agreement between the registrant and certain key employee and executive officer filed exhibit to the registrant quarterly report on form for the quarter ended june file no and incorporated in this document by reference of thermo fisher scientific inc performance restricted stock unit agreement filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of thermo fisher scientific inc restricted stock unit agreement filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of thermo fisher scientific inc stock option agreement for officer filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of performance restricted stock unit agreement between thermo fisher scientific inc and marc casper filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of restricted stock unit agreement between thermo fisher scientific inc and marc casper filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of stock option agreement between thermo fisher scientific inc and marc casper filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of restricted stock unit agreement between thermo fisher scientific inc and marc casper of performance restricted stock unit agreement between thermo fisher scientific inc and marc casper of thermo fisher scientific inc performance restricted stock unit agreement of the registrant of pricewaterhousecoopers llp an independent registered public accounting firm of chief executive officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of of chief financial officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of of chief executive officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of of chief financial officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of insxbrl instance document the instance document doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl document schxbrl taxonomy extension schema document calxbrl taxonomy calculation linkbase document defxbrl taxonomy definition linkbase document labxbrl taxonomy label linkbase document prexbrl taxonomy presentation linkbase document page interactive data file formatted inline xbrl and contained in exhibit _______________________ indicates management contract or compensatory plan contract or arrangement certification is not deemed filed for purpose of section of the exchange act or otherwise subject to the liability of that section such certification is not deemed to be incorporated by reference into any filing under the security act or the exchange act except to the extent that the registrant specifically incorporates it by reference fisher scientific inc index of consolidated financial statement the following consolidated financial statement of the registrant and it subsidiary are required to be included in item page report of independent registered public accounting firmf balance sheet of december and statement of income for the year ended december and statement of comprehensive income for the year ended december and statement of cash flow for the year ended december and statement of shareholder equity for the year ended december and to consolidated financial statementsf of independent registered public accounting firmto the board of director and shareholder of thermo fisher scientific inc opinion on the financial statement and internal control over financial reportingwe have audited the accompanying consolidated balance sheet of thermo fisher scientific inc and it subsidiary the company of december and and the related consolidated statement of income of comprehensive income of shareholder equity and of cash flow for each of the three year in the period ended december including the related note collectively referred to the consolidated financial statement we also have audited the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission coso in our opinion the consolidated financial statement referred to above present fairly in all material respect the financial position of the company of december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with accounting principle generally accepted in the united state of america also in our opinion the company maintained in all material respect effective internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the coso change in accounting principleas discussed in note to the consolidated financial statement the company changed the manner in which it account for lease in basis for opinionsthe company management is responsible for these consolidated financial statement for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in management annual report on internal control over financial reporting appearing under item our responsibility is to express opinion on the company consolidated financial statement and on the company internal control over financial reporting based on our audit we are public accounting firm registered with the public company accounting oversight board united state pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statement are free of material misstatement whether due to error or fraud and whether effective internal control over financial reporting wa maintained in all material respect our audit of the consolidated financial statement included performing procedure to ass the risk of material misstatement of the consolidated financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the consolidated financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the consolidated financial statement our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists and testing and evaluating the design and operating effectiveness of control based on the assessed risk our audit also included performing such other procedure we considered necessary in the circumstance we believe that our audit provide reasonable basis for our opinion definition and limitation of internal control over financial reportinga company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company ii provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and iii provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate critical audit mattersthe critical audit matter communicated below are matter arising from the current period audit of the consolidated financial statement that were communicated or required to be communicated to the audit committee and that relate to account or disclosure that are material to the consolidated financial statement and ii involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which they relate goodwill impairment assessmentas described in note to the consolidated financial statement the company consolidated goodwill balance wa million of december management ass goodwill for impairment at the reporting unit level annually and whenever event occur or circumstance change that would more likely than not reduce the fair value of the reporting unit below it carrying amount management estimate the fair value of it reporting unit by using forecast of discounted future cash flow and peer market multiple the company would record an impairment charge based on the excess of reporting unit carrying amount over it fair value limited to the amount of goodwill disclosed by management estimate of discounted future cash flow require management to make assumption related to revenue and operating income growth rate discount rate and other factor management also considers peer revenue and earnings trading multiple from company that have operational and financial characteristic that are similar to the respective reporting unit and estimate weighted average cost of capital the principal consideration for our determination that performing procedure relating to the goodwill impairment assessment is critical audit matter are the significant judgment by management when estimating the fair value of the reporting unit ii high degree of auditor judgment and effort in performing procedure to evaluate management significant assumption related to discount rate and peer market multiple and iii the audit effort involved the use of professional with specialized skill and knowledge the matter involved performing procedure and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statement these procedure included testing the effectiveness of control relating to the goodwill impairment assessment including control over the valuation of the company reporting unit these procedure also included among others testing management process for developing the fair value estimate evaluating the appropriateness of the discounted cash flow and market model testing the completeness accuracy and relevance of underlying data used in the model and evaluating the significant assumption used by management related to the discount rate the terminal growth rate and peer market multiple evaluating management assumption related to the terminal growth rate involved evaluating whether the assumption used were reasonable considering the consistency with external market data evaluating management assumption related to the peer market multiple involved evaluating the population of peer company used in the analysis and testing selected market data used by management to determine the multiple by comparison to publicly available information professional with specialized skill and knowledge were used to assist in the evaluation of the company discounted cash flow model and the discount rate assumption income taxesas described in note and to the consolidated financial statement the company total income tax expense for the period ended december wa million the company ha deferred income tax liability net of million including valuation allowance of million and unrecognized income tax benefit of million of december disclosed by management the company operates in numerous country under many legal form and result is subject to the jurisdiction of numerous domestic and non tax authority well to tax agreement and treaty among these government determination of taxable income in any jurisdiction requires management to interpret the related tax law and regulation and to use estimate and assumption regarding significant future event such the amount timing and character of deduction permissible revenue recognition method under the tax law and the source and character of income and tax credit management ass income tax position and record tax benefit for all year subject to examination based upon evaluation of the fact circumstance and information available at the reporting date for those tax position where it is more likely than not that tax benefit will be sustained management ha recorded the largest amount of tax benefit with greater than percent likelihood of being realized upon ultimate settlement with taxing authority that ha full knowledge of all relevant information for those income tax position where it is not more likely than not that tax benefit will be sustained no tax benefit ha been recognized in the financial statement management estimate the degree to which tax asset will result in benefit after consideration of all positive and negative evidence and provides valuation allowance for tax asset that it belief will more likely than not go unused in situation in which management ha been able to determine that the company deferred tax asset will be realized that determination generally relies on future reversal of taxable temporary difference and expected future taxable income if it becomes more likely than not that tax asset will be used management revers the related valuation allowance the principal consideration for our determination that performing procedure relating to income tax is critical audit matter are the significant judgment by management when determining the provision for income tax deferred tax asset and liability and liability for unrecognized tax benefit due to numerous and complex tax law the frequency of tax filing well judgment regarding the realizability of deferred tax asset ii high degree of auditor judgment subjectivity and effort in performing procedure and evaluating audit evidence related to the provision for income tax deferred tax asset and liability and liability for unrecognized tax benefit and iii the audit effort involved the use of professional with specialized skill and knowledge addressing the matter involved performing procedure and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statement these procedure included testing the effectiveness of control relating to the provision for income deferred tax asset and liability and liability for unrecognized tax benefit including control over the realizability of deferred tax asset these procedure also included among others testing the accuracy of the income tax provision including the rate reconciliation and permanent and temporary difference ii evaluating whether the data utilized in the calculation of the provision for income tax wa appropriate and consistent with evidence obtained in other area of the audit iii evaluating management assessment of the realizability of deferred tax asset on jurisdictional basis iv evaluating the identification of reserve for unrecognized tax benefit and the reasonableness of the more likely than not determination in consideration of jurisdiction court decision legislative action statute of limitation and development in tax examination testing the calculation of the liability for unrecognized tax benefit by jurisdiction including estimate of the amount of tax benefit expected to be sustained and vi evaluating the adequacy of the company disclosure professional with specialized skill and knowledge were used to assist in evaluating the reasonableness of management judgment and estimate related to the application of foreign and domestic tax law and regulation pricewaterhousecoopers llpboston massachusettsfebruary we have served the company auditor since fisher scientific inc consolidated balance sheet december december in million except share and per share amount asset cash and cash equivalent account receivable le allowance of and contract asset other current total current property plant and equipment acquisition related intangible asset other total asset liability and shareholder equitycurrent liability short term obligation and current maturity of long term obligation account accrued payroll and employee contract other accrued total current deferred income other long term long term commitment and contingency note shareholder equity preferred stock par value share authorized none issuedcommon stock par value share authorized and share capital in excess of par retained treasury stock at cost and share accumulated other comprehensive item total shareholder total liability and shareholder equity the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of income year ended december december december in million except per share amount revenue service total cost and operating expense cost of product cost of service selling general and administrative research and development restructuring and other cost income total cost and operating operating interest interest expense other expense income net income before income provision for income tax net income earnings per sharebasic diluted weighted average the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of comprehensive income year ended december december december in million incomenet income other comprehensive item currency translation adjustment currency translation adjustment net of tax benefit provision of and reclassification adjustment for loss included in net income unrealized gain and loss on hedging instrument unrealized loss on hedging instrument net of tax benefit of and reclassification adjustment for loss included in net income net of tax benefit of and pension and other postretirement benefit liability adjustment pension and other postretirement benefit liability adjustment arising during the period net of tax benefit provision of and amortization of net loss and prior service benefit included in net periodic pension cost net of tax benefit of and total other comprehensive item comprehensive income the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of cash flowsyear endeddecember december december in million activitiesnet income adjustment to reconcile net income to net cash provided by operating activity depreciation of property plant and amortization of acquisition related intangible change in deferred income tax gain on sale of business stock based loss on early extinguishment of debt other non cash expense change in asset and liability excluding the effect of acquisition and disposition account receivable inventory account contribution to retirement plan net cash provided by operating investing activity acquisition net of cash acquired proceeds from sale of business net of cash divested purchase of property plant and equipment proceeds from sale of property plant and other investing activity net net cash used in investing activity financing activitiesnet proceeds from issuance of repayment of debt proceeds from issuance of commercial repayment of commercial paper purchase of company common stock dividend paid net proceeds from issuance of company common stock under employee stock other financing activity net net cash provided by used in financing exchange rate effect on increase in cash cash equivalent and restricted cash cash equivalent and restricted cash at beginning of cash cash equivalent and restricted cash at end of year the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of shareholder equity common stockcapital in excess of par valueretained earningstreasury stockaccumulated other comprehensive itemstotal shareholder equity in million sharesamountsharesamountbalance at december cumulative effect of accounting change issuance of share under employee and director stock stock based compensation purchase of company common stock dividend declared per share net income other comprehensive item other balance at december cumulative effect of accounting change issuance of share under employee and director stock stock based compensation purchase of company common stock dividend declared per share net income other comprehensive item balance at december cumulative effect of accounting change issuance of share under employee and director stock stock based compensation purchase of company common stock dividend declared per share net income other comprehensive item balance at december the accompanying note are an integral part of these consolidated financial statement fisher scientific inc note to consolidated financial statementsnote nature of operation and summary of significant accounting policy nature of operationsthermo fisher scientific inc the company or thermo fisher enables customer to make the world healthier cleaner and safer by helping them accelerate life science research solve complex analytical challenge improve patient diagnostics deliver medicine to market and increase laboratory productivity market served include pharmaceutical and biotech academic and government industrial and applied well healthcare and diagnostics principle of consolidationthe accompanying financial statement include the account of the company and it wholly and majority owned subsidiary all material intercompany account and transaction have been eliminated the company account for investment in business using the equity method when it ha the ability to exercise significant influence but not control generally between and ownership and is not the primary beneficiary presentationcertain reclassification of prior year amount have been made to conform to the current year presentation revenue recognitionconsumables revenue consist of single use product and are recognized at point in time following the transfer of control of such product to the customer which generally occurs upon shipment instrument revenue typically consist of longer lived asset that for the substantial majority of sale are recognized at point in time in manner similar to consumables service revenue clinical trial logistics pharmaceutical development and manufacturing service asset management diagnostic testing training service contract and field service including related time and material are recognized over time customer receive and consume the benefit of such service for revenue recognized over time the company generally us cost accumulated relative to total estimated cost to measure progress this method approximates satisfaction of the performance obligation for contract that contain multiple performance obligation the company allocates the consideration to which it expects to be entitled the transaction price to each performance obligation based on relative standalone selling price and recognizes the related revenue when or control of each individual performance obligation is transferred to customer the company exercise judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer ha the ability to direct the use of and obtain substantially all of the remaining benefit of the asset the company immediately expense contract cost that would otherwise be capitalized and amortized over period of le than one year payment from customer for most instrument and consumables are typically due in fixed number of day after shipment or delivery of the product service arrangement commonly call for payment in advance of performing the work extended service contract upon completion of the service pharmaceutical development and manufacturing or mix of both some arrangement include variable amount of consideration that arise from discount rebate and other program and practice in such arrangement the company estimate the amount by which to reduce the stated contract amount to reflect the transaction price contract related balancesaccounts receivable include amount that have been billed and are currently due from customer they are recorded at the invoiced amount and do not bear interest the company maintains allowance for doubtful account for estimate of expected loss resulting from the inability of it customer to pay amount due the allowance for doubtful account is the company best estimate of the amount of probable credit loss in existing account receivable the company determines the allowance based on history of similarly aged receivables the creditworthiness of the customer reason for delinquency current economic condition expectation associated with future event and circumstance where reasonable and supportable forecast are available and any other information that is relevant to the judgment receivables from academic and government customer well large well capitalized commercial customer have historically experienced le collectability risk account balance are charged against the allowance when the company belief it is probable the receivable will not be recovered the company doe not have any off balance sheet credit exposure related to customer fisher scientific inc note to consolidated financial statement continued the change in the allowance for doubtful account are follows year ended december in million at beginning of year cumulative effect of accounting provision charged to account written off acquisition currency translation and balance at end of year contract asset include revenue recognized in advance of billing and are recorded net of estimated loss resulting from the inability to invoice customer which is primarily due to risk associated with the company performance contract asset are classified current or noncurrent based on the amount of time expected to lapse the company right to consideration becomes unconditional noncurrent contract asset are included within other asset in the accompanying balance sheet contract liability include billing in excess of revenue recognized such those resulting from customer advance and deposit and unearned revenue on service contract contract liability are classified current or noncurrent based on the period over which remaining performance obligation are expected to be transferred to customer noncurrent contract liability are included within other long term liability in the accompanying balance sheet contract asset and liability are presented on net basis in the consolidated balance sheet if they arise from different performance obligation in the contract contract asset and liability balance are follows december december in million contract asset net noncurrent contract asset current contract noncurrent contract substantially all of the current contract liability balance at december and wa recognized in revenue during and respectively warranty obligationsthe company provides for the estimated cost of standard product warranty primarily from historical information in cost of product revenue at the time product revenue are recognized while the company engages in extensive product quality program and process including actively monitoring and evaluating the quality of it component supply the company warranty obligation is affected by product failure rate utilization level material usage service delivery cost incurred in correcting product failure and supplier warranty on part delivered to the company should actual product failure rate utilization level material usage service delivery cost or supplier warranty on part differ from the company estimate revision to the estimated warranty liability would be required the liability for warranty is included in other accrued expense in the accompanying balance sheet extended warranty agreement are considered service contract which are discussed above cost of service contract are recognized incurred the change in the carrying amount of standard product warranty obligation are follows fisher scientific inc note to consolidated financial statement continued year ended december december in million at beginning of year provision charged to usage adjustment to previously provided warranty net currency balance at end of year leasesoperating lease that have commenced are included in other asset other accrued expense and other long term liability in the consolidated balance sheet classification of operating lease liability either current or noncurrent is based on the expected timing of payment due under the company obligation right of use rou asset represent the company right to use an underlying asset for the lease term and lease liability represent the company obligation to make lease payment arising from the lease operating lease rou asset and liability are recognized at the lease commencement date based on the present value of lease payment over the lease term lease with an initial term of month or le are not recorded on the consolidated balance sheet the company recognizes lease expense for these lease on straight line basis over the lease term because most of the company lease do not provide an implicit rate the company estimate incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payment the company us the implicit rate when readily determinable lease term include the effect of option to extend or terminate the lease when it is reasonably certain that the company will exercise that option operating lease expense is recognized on straight line basis over the lease term lessee the company account for the lease and non lease component single lease component research and developmentthe company conduct research and development activity to increase it depth of capability in technology software and service research and development cost include employee compensation and benefit consultant facility related cost material cost depreciation and travel research and development cost are expensed incurred restructuring costsaccounting for the timing and amount of termination benefit provided by the company to employee is determined based on whether the company ha substantive plan to provide such benefit the company ha written employment contract with the affected employee that includes provision for such benefit the termination benefit are due to the occurrence of an event specified in an existing plan or agreement or the termination benefit are one time benefit in certain circumstance employee termination benefit may meet more than one of the characteristic listed above and therefore may have individual element that are subject to different accounting model from time to time when executing restructuring or exit plan the company also incurs cost other than termination benefit such lease termination cost that are not associated with or will not be incurred to generate revenue these include cost that represent amount under contractual obligation that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in penalty to cancel contractual obligation such cost are recognized when incurred which generally occurs at the contract termination or over the period from when plan to abandon leased facility is approved through the cease use date but charge may continue over the remainder of the original contractual period income taxesthe company recognizes deferred income tax based on the expected future tax consequence of difference between the financial statement basis and the tax basis of asset and liability calculated using enacted tax rate in effect for the year in which the difference are expected to be reflected in the tax return fisher scientific inc note to consolidated financial statement continued the financial statement reflect expected future tax consequence of uncertain tax position that the company ha taken or expects to take on tax return presuming the taxing authority full knowledge of the position and all relevant fact but without discounting for the time value of money earnings per sharebasic earnings per share ha been computed by dividing net income by the weighted average number of share outstanding during the year except where the result would be antidilutive to net income diluted earnings per share ha been computed using the treasury stock method for outstanding stock option and restricted unit cash and cash equivalentscash equivalent consists principally of money market fund commercial paper and other marketable security purchased with an original maturity of three month or le these investment are carried at cost which approximates market value inventoriesinventories are valued at the lower of cost or net realizable value cost being determined principally by the first in first out fifo method with certain of the company business utilizing the last in first out lifo method the company periodically review quantity of inventory on hand and compare these amount to the expected use of each product or product line in addition the company ha certain inventory that is subject to fluctuating market pricing the company ass the carrying value of this inventory based on lower of cost or net realizable value analysis the company record charge to cost of sale for the amount required to reduce the carrying value of inventory to net realizable value cost associated with the procurement of inventory such inbound freight charge purchasing and receiving cost and internal transfer cost are included in cost of revenue in the accompanying statement of income the component of inventory are follows december december in million material work in finished inventory the value of inventory maintained using the lifo method wa million and million at december and respectively which wa below estimated replacement cost by million and million respectively reduction to cost of revenue result of the liquidation of lifo inventory were nominal during the three year ended december property plant and equipmentproperty plant and equipment are recorded at cost the cost of addition and improvement are capitalized while maintenance and repair are charged to expense incurred the company generally provides for depreciation and amortization using the straight line method over the estimated useful life of the property follows building and improvement to year machinery and equipment including software to year and leasehold improvement the shorter of the term of the lease or the life of the asset when asset are retired or otherwise disposed of the asset and related accumulated depreciation are eliminated from the account and the resulting gain or loss is reflected in the accompanying statement of income property plant and equipment consists of the following december december in million building and machinery equipment and leasehold property plant and equipment at le accumulated depreciation and property plant and equipment net fisher scientific inc note to consolidated financial statement continued acquisition related intangible assetsacquisition related intangible asset include the cost of acquired customer relationship product technology tradenames and other specifically identifiable intangible asset and are being amortized using the straight line method over their estimated useful life which range from to year in addition the company ha tradenames and in process research and development that have indefinite life and which are not amortized the company review intangible asset for impairment when indication of potential impairment exists such significant reduction in cash flow associated with the asset intangible asset with indefinite life are reviewed for impairment annually or whenever event or change in circumstance indicate they may be impaired acquisition related intangible asset are follows balance at december at december in million grossaccumulated amortizationnetgrossaccumulated amortizationnetdefinite lived customer relationship product other indefinite lived in process research and development acquisition related intangible asset the estimated future amortization expense of acquisition related intangible asset with definite life is follows in million and estimated future amortization expense of definite lived intangible asset other assetsother asset in the accompanying balance sheet include operating lease right of use asset deferred tax asset pension asset cash surrender value of life insurance insurance recovery receivables related to product liability matter investment certain intangible asset and other asset at december and the company had million and million respectively of intangible asset not derived from acquisition net of accumulated amortization which are being amortized using the straight line method over their estimated useful life which range from to year equity investment that do not have readily determinable fair value are measured at cost minus impairment if any plus or minus change resulting from observable price change in orderly transaction for the identical or similar investment of the same issuer the company performs qualitative assessment to identify impairment of these investment at december and the company had such investment with carrying amount of million and million respectively which are included in other asset fisher scientific inc note to consolidated financial statement continued goodwillthe company ass goodwill for impairment at the reporting unit level annually and whenever event occur or circumstance change that would more likely than not reduce the fair value of reporting unit below it carrying amount such event or circumstance generally include the occurrence of operating loss or significant decline in earnings associated with one or more of the company reporting unit the company is permitted to first ass qualitative factor to determine whether the quantitative goodwill impairment test is necessary if the qualitative assessment result in determination that the fair value of reporting unit is more likely than not le than it carrying amount the company performs quantitative goodwill impairment test the company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test the company estimate the fair value of it reporting unit by using forecast of discounted future cash flow and peer market multiple the company would record an impairment charge based on the excess of reporting unit carrying amount over it fair value limited to the amount of goodwill the company determined that no impairment existed in or the change in the carrying amount of goodwill by segment are follows in million life sciencessolutionsanalyticalinstrumentsspecialtydiagnosticslaboratoryproducts andservicestotalbalance at december acquisition finalization of purchase price allocation for acquisition sale of business currency translation balance at december currency balance at december loss contingenciesaccruals are recorded for various contingency including legal proceeding environmental worker compensation product general and auto liability self insurance and other claim that arise in the normal course of business the accrual are based on management judgment historical claim experience the probability of loss and where applicable the consideration of opinion of internal and or external legal counsel and actuarial estimate additionally the company record receivables from third party insurer up to the amount of the loss when recovery ha been determined to be probable liability acquired in acquisition have been recorded at fair value and such were discounted to present value at the date of acquisition currency translationall asset and liability of the company subsidiary operating in non dollar currency are translated at period end exchange rate resulting translation adjustment are reflected in the accumulated other comprehensive item component of shareholder equity revenue and expense are translated at average exchange rate for the period currency transaction gain are included in the accompanying statement of income and in aggregate were million million and million in and respectively derivative contractsthe company is exposed to certain risk relating to it ongoing business operation including change to interest rate and currency exchange rate the company us derivative instrument primarily to manage currency exchange and interest rate risk the company recognizes derivative instrument either asset or liability and measure those instrument at fair value if derivative is hedge depending on the nature of the hedge change in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive item until the hedged item is recognized in earnings derivative that are not designated hedge are recorded at fair value through earnings fisher scientific inc note to consolidated financial statement continued the company us short term forward and option currency exchange contract primarily to hedge certain balance sheet and operational exposure resulting from change in currency exchange rate predominantly intercompany loan and cash balance that are denominated in currency other than the functional currency of the respective operation the currency exchange contract principally hedge transaction denominated in swiss franc euro british pound sterling canadian dollar hong kong dollar japanese yen and czech koruna the company doe not hold or engage in transaction involving derivative instrument for purpose other than risk management cash flow hedge for derivative instrument that are designated and qualify cash flow hedge the gain or loss on the derivative is reported component of other comprehensive item and reclassified into earnings in the same period or period during which the hedged transaction affect earnings and is presented in the same income statement line item the earnings effect of the hedged item fair value hedge for derivative instrument that are designated and qualify fair value hedge the gain or loss on the derivative well the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in earnings net investment hedge the company us foreign currency denominated debt and cross currency interest rate swap to partially hedge it net investment in foreign operation against adverse movement in exchange rate the majority of the company euro denominated senior note and certain of it cross currency interest rate swap have been designated and are effective economic hedge of part of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument and contract fair value change on the cross currency interest rate swap excluding interest accrual are included in currency translation adjustment within other comprehensive item and shareholder equity use of estimatesthe preparation of financial statement in conformity with generally accepted accounting principle requires management to make estimate and assumption that affect the reported amount of asset and liability disclosure of contingent asset and liability at the date of the financial statement and the reported amount of revenue and expense during the reporting period the company estimate include among others asset reserve requirement well the amount of future cash flow associated with certain asset and business that are used in assessing the risk of impairment risk and uncertainty associated with the ongoing covid global pandemic materially adversely affected certain of the company business in particularly in the analytical instrument segment and to lesser extent some business within the other three segment the extent and duration of negative impact continuing into are uncertain and may require change to estimate actual result could differ from those estimate recent accounting pronouncementsin january the fasb issued new guidance to clarify the interaction of the accounting for certain equity security equity method investment and certain forward contract and purchased option among other thing the new guidance clarifies that an entity should consider observable transaction that require it to either apply or discontinue the equity method of accounting for the purpose of applying measurement principle for certain equity security immediately before applying or discontinuing the equity method the company adopted this guidance in using prospective method the adoption of this guidance not have material impact on the company consolidated financial statement in december the fasb issued new guidance to simplify the accounting for income tax among other thing the new guidance requires the effect of enacted change in tax law or rate to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date the company expects to adopt this guidance when it is effective in using prospective method the adoption of this guidance is not expected to have material impact on the company consolidated financial statement however the impact in future period will be dependent on the extent of future event or condition that would be affected such enacted change in tax law or rate in august the fasb issued new guidance to modify the disclosure requirement for employer that sponsor defined benefit pension or other postretirement plan the company adopted the guidance in using retrospective method the adoption of this guidance did not have material impact on the company disclosure in august the fasb issued new guidance to modify the disclosure requirement on fair value measurement the company adopted the guidance in with some item requiring prospective method and others requiring retrospective method the adoption of this guidance did not have material impact on the company disclosure fisher scientific inc note to consolidated financial statement continued in february the fasb issued new guidance to allow reclassification from accumulated other comprehensive item aoci to retained earnings for certain tax effect on item within aoci resulting from the tax cut and job act of the tax act the company adopted this guidance in january and recorded the reclassification in the period of adoption the adoption of this guidance increased retained earnings and reduced accumulated other comprehensive item by million and million respectively on january this guidance only relates to the effect of the tax act for all other tax law change that have occurred or may occur in the future the company reclassifies the tax effect to the consolidated statement of income on an item by item basis when the pre tax item in aoci is reclassified to income in december the sec staff issued guidance to address the application of accounting guidance in situation when registrant doe not have the necessary information available prepared or analyzed including computation in reasonable detail to complete the accounting for certain income tax effect of the tax act enacted on december the company reported provisional amount in it financial statement for certain income tax effect of the tax act for which reasonable estimate could be determined adjustment to provisional amount identified during the measurement period which ended december are included adjustment to provision for income tax in in august the fasb issued new guidance to simplify the application of hedge accounting guidance among other thing the new guidance will permit more hedging strategy to qualify for hedge accounting allow for additional time to perform an initial assessment of hedge effectiveness and permit qualitative effectiveness test for certain hedge after initial qualification the company adopted this guidance in january the adoption of this guidance increased retained earnings by million on january in october the fasb issued new guidance eliminating the deferral of the tax effect of intra entity asset transfer the impact of this guidance in future period will be dependent on the extent of future asset transfer which usually occur in connection with planning around acquisition and other business structuring activity the adoption of this guidance reduced retained earnings by million on january in june the fasb issued new guidance to require financial asset measured at amortized cost basis such account receivable to be presented at the net amount expected to be collected based on relevant information about past event including historical experience current condition and reasonable and supportable forecast that affect the collectability of the reported amount during and the fasb issued additional guidance and clarification the company adopted the guidance in using modified retrospective method the adoption of this guidance reduced account receivable and retained earnings by million on january in february the fasb issued new guidance which requires lessee to record most lease on their balance sheet lease liability initially measured at the present value of the future lease payment with corresponding right of use asset the new guidance also set forth new disclosure requirement related to lease during the fasb issued additional guidance and clarification the company adopted this guidance in january the company elected to adopt the guidance using modified retrospective method by applying the transition approach of the beginning of the period of adoption comparative period have not been restated permitted upon transition the company did not reassess whether any expired or existing contract were or contained embedded lease the lease classification for any expired or existing lease initial direct cost for any lease or whether land easement met the definition of lease if they were not accounted for lease under the prior guidance the adoption of this guidance increased retained earnings by million on january in january the fasb issued new guidance which affect the accounting for equity investment financial liability under the fair value option and the presentation and disclosure requirement for financial instrument this guidance requires equity investment to be measured at fair value with subsequent change recognized in net income except for those accounted for under the equity method or requiring consolidation the guidance also change the accounting for investment without readily determinable fair value and that do not qualify for the practical expedient permitted by the guidance to estimate fair value the adoption of this guidance reduced retained earnings and increased accumulated other comprehensive item by million on january in may the fasb issued new revenue recognition guidance which provides single comprehensive model for entity to use in accounting for revenue arising from contract with customer and supersedes most previous revenue recognition guidance the new standard also requires significantly expanded disclosure regarding the qualitative and quantitative information of an entity nature amount timing and uncertainty of revenue and cash flow arising from contract with customer during and the fasb issued additional guidance and clarification including the elimination of certain sec staff guidance the guidance is effective for the company in the company elected to adopt this guidance through application of the modified retrospective method by applying it to contract that were not completed of december in addition to new contract in and thereafter the adoption of this guidance increased retained earnings by million on january fisher scientific inc note to consolidated financial statement continued note acquisition and dispositionsthe company acquisition have historically been made at price above the determined fair value of the acquired identifiable net asset resulting in goodwill primarily due to expectation of the synergy that will be realized by combining the business these synergy include the elimination of redundant facility function and staffing use of the company existing commercial infrastructure to expand sale of the acquired business product and use of the commercial infrastructure of the acquired business to cost effectively expand sale of company product acquisition have been accounted for using the acquisition method of accounting and the acquired company result have been included in the accompanying financial statement from their respective date of acquisition acquisition transaction cost are recorded in selling general and administrative expense incurred the company acquired within the life science solution segment based provider of spectral dye platform for high resolution biology application which will extend the company existing tool for protein and cell analysis application for total purchase price of million including the fair value of contingent consideration april the company acquired within the laboratory product and service segment brammer bio for approximately billion in cash brammer bio is leading viral vector contract development and manufacturing organization for gene and cell therapy the acquisition expanded the segment contract manufacturing capability the purchase price exceeded the fair value of the identifiable net asset and accordingly million wa allocated to goodwill million of which is tax deductible in addition in the company acquired within the analytical instrument segment slovakia based provider of mass spectrometry software used for identification of compound and within the laboratory product and service segment an active pharmaceutical ingredient manufacturing facility in cork ireland for an aggregate purchase price of million the component of the purchase price and net asset acquired for acquisition are follows in million brammer bioothertotalpurchase pricecash paid cash acquired net asset acquiredcurrent asset property plant and definite lived intangible asset customer product other contract liability deferred tax liability other liability assumed the weighted average amortization period for definite lived intangible asset acquired in are year for customer relationship year for product technology and year for tradenames the weighted average amortization period for all definite lived intangible asset acquired in is year fisher scientific inc note to consolidated financial statement continued october the company acquired within the life science solution segment becton dickinson and company advanced bioprocessing business for million in cash this north america based business add complementary cell culture product that expanded the segment bioproduction offering to help customer increase yield during production of biologic drug the purchase price exceeded the fair value of the identifiable net asset and accordingly million wa allocated to goodwill all of which is tax deductible in the company acquired within the life science solution segment north america based provider of rapid dna platform for use in forensics and law enforcement application for an aggregate purchase price of million the component of the purchase price and net asset acquired for acquisition are follows in million advanced bioprocessing businessothertotalpurchase pricecash paid fair value of contingent consideration cash acquired net asset acquiredcurrent asset property plant and definite lived intangible asset customer product indefinite lived intangible asset in process research and development other asset deferred tax liability other liability assumed the weighted average amortization period for definite lived intangible asset acquired in are year for customer relationship year for product technology and year for tradenames the weighted average amortization period for all definite lived intangible asset acquired in is year dispositionon june the company sold it anatomical pathology business to phc holding corporation for billion net of cash divested the business wa part of the specialty diagnostics segment the sale of this business resulted in pre tax gain of approximately million included in restructuring and other income cost net revenue in through the date of sale and the full year of the business sold were approximately million and million respectively net of retained sale through the company healthcare market and research and safety market channel business fisher scientific inc note to consolidated financial statement continued note revenue disaggregated revenuesrevenues by type are follows in million consolidated revenue revenue by geographic region based on customer location are follows in million america asia other consolidated revenue each reportable segment earns revenue from consumables instrument and service in north america europe asia pacific and other region see note for revenue by reportable segment and other geographic data remaining performance obligationsthe aggregate amount of the transaction price allocated to the remaining performance obligation for all open customer contract of december wa billion the company will recognize revenue for these performance obligation they are satisfied approximately of which is expected to occur within the next twelve month note business segment and geographical information the company financial performance is reported in four segment description of each segment follows life science solution provides an extensive portfolio of reagent instrument and consumables used in biological and medical research discovery and production of new drug and vaccine well diagnosis of disease including covid through it polymerase chain reaction pcr testing and sample preparation capability these product and service are used by customer in pharmaceutical biotechnology agricultural clinical academic and government market analytical instrument provides broad offering of instrument consumables software and service that are used for range of application in the laboratory on the production line and in the field these product and service are used by customer in pharmaceutical biotechnology academic government environmental and other research and industrial market well the clinical laboratory specialty diagnostics provides wide range of diagnostic test kit reagent culture medium instrument and associated product used to increase the speed and accuracy of diagnosis these product are used by customer in healthcare clinical pharmaceutical industrial and food safety laboratory laboratory product and service provides virtually everything needed for the laboratory including combination of self manufactured and sourced product for customer in research academic government industrial and healthcare setting the segment also includes comprehensive offering of outsourced service used by the pharmaceutical and biotech industry for drug development clinical trial logistics and commercial drug manufacturing the company management evaluates segment operating performance based on operating income before certain charge credit to cost of revenue and selling general and administrative expense principally associated with acquisition accounting restructuring and other cost income including cost arising from facility consolidation such severance and abandoned lease fisher scientific inc note to consolidated financial statement continued expense and gain and loss from the sale of real estate and product line well from significant litigation related matter and amortization of acquisition related intangible asset the company us this measure because it help management understand and evaluate the segment core operating result and facilitates comparison of performance for determining compensation business segment information in million science solution analytical specialty laboratory product and elimination consolidated segment incomelife science analytical specialty laboratory product and subtotal reportable cost of revenue charge net selling general and administrative credit charge restructuring and other cost income net amortization of acquisition related intangible asset consolidated operating interest interest expense other expense income net income before income tax depreciationlife science solution analytical specialty laboratory product and consolidated depreciation fisher scientific inc note to consolidated financial statement continued in million assetslife science solution analytical specialty laboratory product and corporate other consolidated total asset capital expenditureslife science solution analytical specialty laboratory product and corporate consolidated capital expenditure corporate asset consist primarily of cash and cash equivalent and property and equipment at the company corporate office geographical information in million united state consolidated revenue long lived asset united state consolidated long lived asset revenue are attributed to country based on customer location includes property plant and equipment net and beginning in operating lease rou asset note other expense income net in all period other expense income net includes currency transaction gain and loss on monetary asset and liability and net periodic pension benefit cost income excluding the service cost component which is included in operating expense on the accompanying statement of income in other expense net includes million of financing cost for terminated acquisition primarily for loan commitment fee and entering into hedging contract offset in part by million of net gain on investment the company had cash outlay of million in associated with obtaining the loan commitment included in other financing activity net in the accompanying statement of cash flow in other expense net includes million of loss on the early extinguishment of debt note offset in part by million of net gain on investment the investment gain include million gain on the sale of joint venture for net proceeds of million in other expense net includes million of net loss on investment fisher scientific inc note to consolidated financial statement continued note stock based compensation expense the company ha stock based compensation plan for it key employee director and others these plan permit the grant of variety of stock and stock based award including restricted stock unit stock option or performance based share determined by the compensation committee of the company board of director or for certain non officer grant by the company employee equity committee which consists of it chief executive officer the company generally issue new share of it common stock to satisfy option exercise and restricted unit vesting grant of stock option and restricted unit generally provide that in the event of both change in control of the company and qualifying termination of an option or unit holder employment all option and service based restricted unit award held by the recipient become immediately vested unless an employment or other agreement with the employee provides for different treatment compensation cost is based on the grant date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility if earlier and is primarily included in selling general and administrative expense stock optionsthe company practice is to grant stock option at fair market value option vest over year with term of year assuming continued employment with certain exception vesting of the option award is contingent upon meeting certain service condition the fair value of most option grant is estimated using the black scholes option pricing model for option grant that require the achievement of both service and market condition lattice model is used to estimate fair value the fair value is then amortized on straight line basis over the requisite service period of the award which is generally the vesting period use of valuation model requires management to make certain assumption with respect to selected model input expected volatility wa calculated based on the historical volatility of the company stock historical data on exercise pattern is the basis for estimating the expected life of an option the risk free interest rate is based on treasury zero coupon issue with remaining term which approximates the expected life assumed at the date of grant the expected annual dividend rate wa calculated by dividing the company annual dividend based on the most recent quarterly dividend rate by the closing stock price on the grant date the compensation expense recognized for all stock based award is net of estimated forfeiture forfeiture are estimated based on an analysis of actual option forfeiture the weighted average assumption used in the black scholes option pricing model are follows stock price risk free interest expected life of option year annual the weighted average per share grant date fair value of option granted during and were and respectively the total intrinsic value of option exercised during the same period wa million million and million respectively the intrinsic value is the difference between the market value of the share on the exercise date and the exercise price of the option fisher scientific inc note to consolidated financial statement continued summary of the company option activity for the year ended december is presented below share in million weighted average exercise priceweighted average remaining contractual term in year aggregate intrinsic value in million outstanding at december exercised canceled expired outstanding at december and unvested expected to vest at december exercisable at december of december there wa million of total unrecognized compensation cost related to unvested stock option granted the cost is expected to be recognized through with weighted average amortization period of year restricted share unit awardsawards of restricted unit convert into an equivalent number of share of common stock the award generally vest over year assuming continued employment with some exception vesting of the award is contingent upon meeting certain service condition and may also be contingent upon meeting certain performance and or market condition the fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award which is generally the vesting period recipient of restricted unit have no voting right but are entitled to accrue dividend equivalent the fair value of service and performance based restricted unit award is determined based on the number of unit granted and the market value of the company share on the grant date for award with market based vesting condition the company us lattice model to estimate the grant date fair value of the award summary of the company restricted unit activity for the year ended december is presented below unit in million weightedaveragegrant datefair valueunvested at december vested forfeited unvested at december the total fair value of share vested during and wa million million and million respectively of december there wa million of total unrecognized compensation cost related to unvested restricted stock unit award the cost is expected to be recognized through with weighted average amortization period of year employee stock purchase plansqualifying employee are eligible to participate in an employee stock purchase plan sponsored by the company share may be purchased under the program at of the fair market value at the end of the purchase period and the share purchased are not subject to holding period share are purchased through payroll deduction of up to of each participating employee qualifying gross wage the company issued million million and million share respectively of it common stock in and under the employee stock purchase plan fisher scientific inc note to consolidated financial statement continued note pension and other postretirement benefit plan saving plan and other defined contribution plansthe company saving and other defined contribution plan cover the majority of the company eligible and certain non employee contribution to the plan are made by both the employee and the company company contribution are based on the level of employee contribution company contribution to these plan are based on formula determined by the company in and the company charged to expense million million and million respectively related to it defined contribution plan defined benefit pension plansemployees of number of the company non and certain subsidiary participate in defined benefit pension plan covering substantially all full time employee at those subsidiary some of the plan are unfunded permitted under the plan and applicable law the company also maintains postretirement healthcare program at several acquired business where certain employee are eligible to participate the cost of the postretirement healthcare program are generally funded on self insured and insured premium basis the company recognizes the funded status of defined benefit pension and other postretirement benefit plan an asset or liability this amount is defined the difference between the fair value of plan asset and the benefit obligation the company is required to recognize component of other comprehensive item net of tax the actuarial gain loss and prior service cost credit that arise but were not previously required to be recognized component of net periodic benefit cost other comprehensive item is adjusted these amount are later recognized in income component of net periodic benefit cost when company with pension plan is acquired any excess of projected benefit obligation over the plan asset is recognized liability and any excess of plan asset over the projected benefit obligation is recognized an asset the recognition of new liability or new asset result in the elimination of previously existing unrecognized net gain or loss and unrecognized prior service cost or credit the company fund annually at minimum the statutorily required minimum amount actuarially determined during and the company made cash contribution of approximately million million and million respectively contribution to the plan included in the following table are estimated at between and million for fisher scientific inc note to consolidated financial statement continued the following table provides reconciliation of benefit obligation and plan asset of the company domestic and non pension plan and postretirement benefit plan domestic pension benefitsnon pension benefitspostretirementbenefits in million in projected benefit obligationsbenefit obligation at beginning of year divestiture service cost interest settlement plan participant contribution actuarial gain benefit paid currency translation and other benefit obligation at end of year change in fair value of plan assetsfair value of plan asset at beginning of year divestiture actual return on plan employer settlement plan participant contribution benefit paid currency translation and other fair value of plan asset at end of year funded status accumulated benefit obligation amount recognized in balance sheetnoncurrent asset current liability noncurrent liability net amount recognized amount recognized in accumulated other comprehensive itemsnet actuarial loss prior service credit net amount recognized for both domestic and non pension plan actuarial loss experienced in and were principally driven by decrease in the weighted average discount rate that were used to determine the projected benefit obligation for domestic pension plan the actuarial loss were partially offset by gain recognized due to the adoption of an updated mortality assumption fisher scientific inc note to consolidated financial statement continued the actuarial assumption used to compute the funded status for the plan are based upon information available of december and and are follows domestic pensionbenefitsnon pensionbenefitspostretirementbenefits average assumption used to determine projected benefit obligationsdiscount rate for determining benefit interest crediting rate for cash balance an aaverage rate of increase in employee compensationn an an ainitial healthcare cost trend ultimate healthcare cost trend the ultimate healthcare cost trend rate for the postretirement benefit plan are expected to be reached between and the actuarial assumption used to compute the net periodic pension benefit cost income are based upon information available of the beginning of the year presented in the following table domestic pension benefitsnon pension benefit average assumption used to determine net benefit cost income discount rate service costn an an discount rate interest average rate of increase in employee compensationn an an expected long term rate of return on the discount rate reflects the rate the company would have to pay to purchase high quality investment that would provide cash sufficient to settle it current pension obligation the discount rate is determined based on range of factor including the rate of return on high quality fixed income corporate bond and the related expected duration of the obligation or in certain instance the company ha used hypothetical portfolio of high quality instrument with maturity that mirror the benefit obligation in order to accurately estimate the discount rate relevant to particular plan the company utilizes full yield curve approach in the estimation of these component by applying the specific spot rate along the yield curve used in the determination of the benefit obligation to the relevant projected cash flow the expected long term rate of return on plan asset reflects the average rate of earnings expected on the fund invested or to be invested to provide for the benefit included in the projected benefit obligation in determining the expected long term rate of return on plan asset the company considers the relative weighting of plan asset the historical performance of total plan asset and individual asset class and economic and other indicator of future performance in addition the company may consult with and consider the opinion of financial and other professional in developing appropriate return benchmark asset management objective include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirement the expected rate of compensation increase reflects the long term average rate of salary increase and is based on historic salary increase experience and management expectation of future salary increase fisher scientific inc note to consolidated financial statement continued the projected benefit obligation and fair value of plan asset for the company qualified and non qualified pension plan with projected benefit obligation in excess of plan asset are follows pension plan in million plan with projected benefit obligation in excess of plan assetsprojected benefit obligation fair value of plan the accumulated benefit obligation and fair value of plan asset for the company qualified and non qualified pension plan with accumulated benefit obligation in excess of plan asset are follows pension plan in million plan with accumulated benefit obligation in excess of plan assetsaccumulated benefit obligation fair value of plan the measurement date used to determine benefit information is december for all plan asset and benefit obligation the net periodic pension benefit cost income includes the following component domestic pension benefitsnon pension benefit in million of net benefit cost income service cost benefit earned interest cost on benefit expected return on plan asset amortization of actuarial net amortization of prior service benefit settlement curtailment loss net periodic benefit cost income the net periodic postretirement benefit cost wa not material in and expected benefit payment are estimated using the same assumption used in determining the company benefit obligation at december benefit payment will depend on future employment and compensation level average year employed and average life span among other factor and change in any of these factor could significantly affect these estimated future benefit payment estimated future benefit payment during the next five year and in the aggregate for the five fiscal year thereafter are follows in million domesticpensionbenefitsnon pensionbenefitspost retirementbenefitsexpected benefit fisher scientific inc note to consolidated financial statement continued domestic pension plan assetsthe company overall objective is to manage the asset in liability framework where investment are selected that are expected to have similar change in fair value the related liability will have upon change in interest rate the company invests in portfolio of both return seeking and liability hedging asset primarily through the use of institutional collective fund to achieve long term growth and to insulate the funded position from interest rate volatility the strategic asset allocation us combination of risk controlled and index strategy in fixed income and global equity the target allocation for the investment are approximately to fund investing in equity approximately to fund investing in international equity and approximately to fund investing in fixed income security the portfolio maintains enough liquidity at all time to meet the near term benefit payment non pension plan assetsthe company maintains specific plan asset for many of the individual pension plan outside the the investment strategy of each plan ha been uniquely established based on the country specific standard and characteristic of the plan several of the plan have contract with insurance company whereby the market risk of the benefit obligation are borne by the insurance company when asset are held directly in investment generally the objective is to invest in portfolio of diversified asset with variety of fund manager the investment may include equity fund fixed income fund hedge fund multi asset fund alternative investment and derivative fund with the target asset allocation ranging from approximately for equity fund for fixed income fund for hedge fund for multi asset fund to for alternative investment and for fund holding derivative the derivative held by the fund are primarily interest rate swap intended to match the movement in the plan liability well equity future in synthetic equity fund which provide targeted exposure to equity market without the fund holding individual equity position each plan maintains enough liquidity at all time to meet the near term benefit payment the fair value of the company plan asset at december and by asset category are follows december quoted pricesin activemarketssignificantotherobservableinputssignificantunobservableinputsnot subject to leveling in million level level level domestic pension plan assetsu equity fund international equity fixed income money market total domestic pension plan non pension plan assetsequity fund fixed income hedge multi asset derivative alternative insurance cash money market total non pension plan investment measured at the net asset value per share or it equivalent practical expedient have not been classified in the fair value hierarchy fisher scientific inc note to consolidated financial statement continued december quoted pricesin activemarketssignificantotherobservableinputssignificantunobservableinputsnot subject to leveling in million level level level domestic pension plan assetsu equity fund international equity fixed income money market total domestic pension plan non pension plan assetsequity fund fixed income hedge multi asset derivative alternative insurance cash money market total non pension plan investment measured at the net asset value per share or it equivalent practical expedient have not been classified in the fair value hierarchy the table above present the fair value of the company plan asset in accordance with the fair value hierarchy note certain investment that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy the fair value amount of these investment presented in the above table are intended to permit reconciliation of the fair value hierarchy to the amount presented for the total pension plan asset these investment were also redeemable at the balance sheet date or within limited time restriction note income taxesthe component of income before provision for income tax are follows in million non income before income tax fisher scientific inc note to consolidated financial statement continued the component of the provision for income tax are follows in million income tax provisionfederal non deferred income tax provision benefit federal non state provision for income tax the provision for income tax in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income tax due to the following in million federal income tax provision for income tax at statutory rate increase decrease resulting from foreign rate differential income tax credit global intangible low taxed foreign derived intangible income excess tax benefit from stock option and restricted stock unit provision for reversal of tax reserve net intra entity transfer foreign exchange loss on inter company debt refinancing domestication transaction valuation transition tax and other impact of tax reform withholding basis difference on disposal of business tax return reassessment and settlement state income tax net of federal other net provision for income tax the company ha operation and taxable presence in approximately country outside the the company effective income tax rate differs from the federal statutory rate each year due to certain operation that are subject to tax incentive state and local tax and foreign tax that are different than the federal statutory rate during the company settled an irs audit relating to the and tax year the company recorded million net tax benefit primarily from this settlement and related impact which resulted in decrease in the company unrecognized tax benefit of million of which million wa reclassified to income tax payable the company recorded million of charge for expired tax credit and other related component of the settlement the company recorded fisher scientific inc note to consolidated financial statement continued charge of million to establish valuation allowance against certain foreign tax credit which the company belief will more likely than not expire unutilized tax cut and job act of december the tax cut and job act of wa enacted the tax act includes significant change to existing tax law that affect the company including reduction of the corporate income tax rate beginning in and creation of territorial tax system with one time transition tax on deemed repatriated earnings and profit of foreign subsidiary transition tax the company recognized net charge for certain aspect of the tax act in it financial statement for which the accounting wa provisional but reasonable estimate could be determined during the company completed it accounting for the income tax effect of the tax act and recognized net adjustment detailed below to the provisional amount totaling net charge of million component of income tax expense the transition tax is based on the company total post earnings and profit the tax on which wa previously deferred from income tax under law the company recorded provisional amount for the transition tax liability for each of the foreign subsidiary at december after further analysis of new treasury guidance available tax accounting method and election legislative update regulation earnings and profit computation and foreign tax the company finalized the calculation of the transition tax liability during the increase in the liability for the transition tax in consisted of an incremental provision of million offset in part by million reduction of related unrecognized tax benefit established in during the company recorded net tax provision of million to adjust the impact of tax reform based on final regulation issued by the treasury in the income tax provision consists of an incremental charge of million offset by million reduction of related unrecognized tax benefit the tax act included provision for global intangible low taxed income the company ha adopted policy to account for this provision period cost other tax impactsin the company recorded million income tax benefit related to domestication transaction involving the transfer of certain non subsidiary to the including interest expense of those subsidiary the company also recorded valuation allowance of million against the amount of interest expense that the company belief will more likely than not go unused also in the company recorded million income tax benefit including both federal and state tax related to foreign exchange loss for tax purpose on certain intercompany financing arrangement in the company recorded million income tax benefit including both federal and state tax related to foreign exchange loss for tax purpose on certain intercompany financing arrangement well tax provision of million related to the gain on the sale of the anatomical pathology business also in the company recorded million benefit related to the deferred tax implication of intra entity transaction which included tax benefit to release valuation allowance against net operating loss previously determined to be unrealizable in the provision for income tax also included million charge to establish valuation allowance against net operating loss that will not be utilized result of the sale of the anatomical pathology business note the foreign tax credit discussed below are the result of foreign earnings and profit remitted or deemed remitted to the during the reporting year and the treatment of tax paid in the foreign jurisdiction in the year those profit were originally earned in the company implemented foreign tax credit planning in sweden which resulted in million of foreign tax credit with no related incremental income tax expense in the company implemented foreign tax credit planning in sweden which resulted in million of foreign tax credit with no related incremental income tax expense the company generally receives tax deduction upon the exercise of non qualified stock option by employee or the vesting of restricted stock unit held by employee for the difference between the exercise price and the market price of the underlying common stock on the date of exercise the company us the incremental tax benefit approach for utilization of tax attribute these excess tax benefit reduce the tax provision in and the company tax provision wa reduced by million million and million respectively of such benefit fisher scientific inc note to consolidated financial statement continued net deferred tax asset liability in the accompanying balance sheet consists of the following in million tax asset liability depreciation and amortization net operating loss and credit reserve and accrued inventory basis deferred other capitalized unrealized loss on hedging other deferred tax asset liability net before valuation allowance le valuation deferred tax asset liability net the company estimate the degree to which tax asset and loss and credit carryforwards will result in benefit based on expected profitability by tax jurisdiction and provides valuation allowance for tax asset and loss and credit carryforwards that it belief will more likely than not expire unutilized at december all of the company valuation allowance relates to deferred tax asset primarily net operating loss and disallowed interest expense carryforward for which any subsequently recognized tax benefit will reduce income tax expense the change in the valuation allowance are follows year ended december in million at beginning of year addition reduction charged to income tax provision addition due to acquisition reduction due to divestiture deduction currency translation and balance at end of year at december the company had federal state and non net operating loss carryforwards of million billion and billion respectively use of the carryforwards is limited based on the future income of certain subsidiary the federal and state net operating loss carryforwards expire in the year through of the non net operating loss carryforwards billion expire in the year through and the remainder do not expire at december the company had foreign tax credit carryforwards of million and deferred interest carryforwards of million the foreign tax credit carryforwards will expire in the year through while deferred interest carryforwards do not expire result of the tax act federal tax have been recorded on billion of undistributed foreign earnings of december provision ha not been made for certain state income tax or additional non tax that would be due when cash is repatriated to the the company undistributed foreign earnings are intended to be reinvested outside of the indefinitely the determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed the company intent is to only make distribution from non subsidiary in the future when they can be made at no net tax cost fisher scientific inc note to consolidated financial statement continued unrecognized tax benefitsas of december the company had billion of unrecognized tax benefit substantially all of which if recognized would reduce the effective tax rate reconciliation of the beginning and ending amount of unrecognized tax benefit is follows in million at beginning of year reduction due to acquisition addition for tax position of current addition for tax position of prior year reduction for tax position of prior year closure of tax year settlement balance at end of year substantially all of the unrecognized tax benefit are classified long term liability the company doe not expect it unrecognized tax benefit to change significantly over the next twelve month during the company unrecognized tax benefit decreased million result of uncertain tax position relating to foreign tax position and million relating to federal and state tax position which included million from the settlement of the irs audit of the and tax year during the company unrecognized tax benefit increased million result of uncertain tax position relating to foreign tax position and million relating to federal and state tax position during the company unrecognized tax benefit increased million result of uncertain tax position relating to foreign tax position and million relating to federal and state tax position the company classified interest and penalty related to unrecognized tax benefit income tax expense the total amount of interest and penalty related to uncertain tax position and recognized in the balance sheet of december and wa million and million respectively the company conduct business globally and result thermo fisher or one or more of it subsidiary file income tax return in the federal jurisdiction and various state and foreign jurisdiction in the normal course of business the company is subject to examination by taxing authority throughout the world including such major jurisdiction australia canada china denmark finland france germany japan singapore sweden the united kingdom and the united state with few exception the company is no longer subject to state and local or non income tax examination for year before and no longer subject to federal income tax examination for year before note earnings per share in million except per share amount income basic weighted average plus effect of stock option and restricted diluted weighted average basic earnings per share diluted earnings per share antidilutive stock option excluded from diluted weighted average fisher scientific inc note to consolidated financial statement continued note debt and other financing arrangement effective interest rate at december december december dollar in million rate year senior note due euro denominated year senior note due euro denominated year senior note due year senior note due year senior note due euro denominated year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due euro denominated year senior note due euro denominated year senior note due year senior note due year senior note due euro denominated year senior note due euro denominated year senior note due euro denominated year senior note due euro denominated year senior note due year senior note due year senior note due euro denominated other total borrowing at par fair value hedge accounting unamortized discount unamortized debt issuance cost total borrowing at carrying le short term obligation and current long term obligation the effective interest rate for the fixed rate debt include the stated interest on the note the accretion of any discount or amortization of any premium the amortization of any debt issuance cost and if applicable adjustment related to hedging see note for fair value information pertaining to the company long term obligation fisher scientific inc note to consolidated financial statement continued of december the annual repayment requirement for debt obligation are follows in million and in addition to available borrowing under the company revolving credit agreement discussed below the company had unused line of credit of million of december these unused line of credit generally provide for short term unsecured borrowing at various interest rate credit facilitiesthe company ha revolving credit facility the facility with bank group that provides for up to billion of unsecured multi currency revolving credit the facility expires on december the revolving credit agreement call for interest at either libor based rate or libor successor rate euribor based rate for fund drawn in euro or rate based on the prime lending rate of the agent bank at the company option the agreement contains affirmative negative and financial covenant and event of default customary for facility of this type the covenant in the facility include consolidated net interest coverage ratio consolidated ebitda to consolidated net interest expense such term are defined in the facility specifically the company ha agreed that so long any lender ha any commitment under the facility any letter of credit is outstanding under the facility or any loan or other obligation is outstanding under the facility it will maintain minimum consolidated interest coverage ratio of of the last day of any fiscal quarter of december no borrowing were outstanding under the facility although available capacity wa reduced by approximately million result of outstanding letter of credit commercial paper programsthe company ha commercial paper program pursuant to which it may issue and sell unsecured short term promissory note cp note under the program maturity may not exceed day from the date of issue and the cp note are issued on private placement basis under customary term in the commercial paper market and are not redeemable prior to maturity subject to voluntary prepayment under the euro program maturity may not exceed day and may be denominated in euro dollar japanese yen british pound sterling swiss franc canadian dollar or other currency under both program the cp note are issued at discount from par or premium to par in the case of negative interest rate or alternatively are sold at par and bear varying interest rate on fixed or floating basis of december there were no outstanding borrowing under these program senior notesinterest is payable annually on the euro denominated senior note and semi annually on all other senior note each of the note may be redeemed at redemption price of of the principal amount plus specified make whole premium and accrued interest the company is subject to certain affirmative and negative covenant under the indenture governing the senior note the most restrictive of which limit the ability of the company to pledge principal property security under borrowing arrangement the company wa in compliance with all covenant at december in the company refinanced certain of it debt by issuing new senior note and using the proceeds to redeem some of it existing senior note in connection with these redemption the company incurred million of loss on the early extinguishment of debt included in other expense net on the accompanying statement of income upon redemption of the senior note the company terminated the related fixed to floating rate interest rate swap arrangement and paid million included in other financing activity net in the accompanying statement of cash flow the company also terminated related cross currency interest rate swap arrangement and received million included in other investing activity net in the accompanying statement of cash flow fisher scientific inc note to consolidated financial statement continued interest rate swap arrangementsthe company ha entered into libor based interest rate swap arrangement with various bank the aggregate amount of the swap are equal to the principal amount of the note and the payment date of the swap coincide with the interest payment date of the note the swap contract provide for the company to pay variable interest rate and receive fixed rate the variable interest rate reset monthly the swap have been accounted for fair value hedge of the note see note for additional information on the interest rate swap arrangement and related cross currency interest rate swap arrangement the following table summarizes the outstanding interest rate swap arrangement on the company senior note at december aggregate notional amountpay rate of dollar in million pay ratedecember senior note due month libor the payment on million notional value of these interest rate swap are offset in part by cross currency interest rate swap which effectively reduced the pay rate of december from to weighted average of the company ha entered into million notional value of cross currency interest rate swap which effectively convert portion of the semi annual payment related to the variable rate dollar denominated libor based interest rate swap to payment on variable rate euro denominated euribor based cross currency interest rate swap debt redemptionsin december the company gave notice of it intention to redeem the following senior note in january principal value in million year senior note due euro denominated year senior note due year senior note due the redemption were completed on january in connection with the redemption the company received million upon the termination of the fixed to floating rate swap arrangement on the redeemed senior note the company incurred approximately million of loss on the early extinguishment of debt in january due to these redemption note leasesas lessee the company lease certain logistics office and manufacturing facility well vehicle copier and other equipment these operating lease generally have remaining lease term between month and year and some include option to extend generally for to year or have option to terminate the arrangement within year the company finance lease are not material the company ha guaranteed the residual value of three leased operating facility with lease term ending in and the company ha agreed with the lessor to comply with certain financial covenant consistent with it other debt arrangement note the aggregate maximum guarantee under these three lease arrangement is million operating lease rou asset and lease liability for these lease arrangement are recorded on the consolidated balance sheet of december but exclude any amount for residual value guarantee fisher scientific inc note to consolidated financial statement continued lessee the consolidated financial statement include the following in million sheetrou asset operating lease liability operating lease liability statement of incomeoperating lease cost variable lease statement of cash flowscash used in operating activity for payment of amount included in the measurement of operating lease liability operating lease rou asset obtained in exchange for new operating lease weighted average at end of yearremaining operating lease yearsdiscount rou asset are classified in other asset in the consolidated balance sheet operating lease liability are classified in other accrued expense and other long term liability respectively in the consolidated balance sheet lease cost arising from finance lease short term lease and sublease income are not material of december future payment of operating lease liability are follows in million and total lease le imputed total operating lease liability lessor operating lease sale type lease and direct financing lease are not material under previous lease accounting guidance net income includes expense from operating lease of million in fisher scientific inc note to consolidated financial statement continued note commitment and contingency purchase obligationsthe company ha entered into unconditional purchase obligation in the ordinary course of business that include agreement to purchase good service or fixed asset and to pay royalty that are enforceable and legally binding and that specify all significant term including fixed or minimum quantity to be purchased fixed minimum or variable price provision and the approximate timing of the transaction purchase obligation exclude agreement that are cancelable at any time without penalty the aggregate amount of the company unconditional purchase obligation totaled billion at december and the majority of these obligation are expected to be settled during the analytical instrument segment recorded charge to cost of product revenue for million in related to an existing supply contract for component of electron microscopy instrument the agreement requires the company to make future minimum purchase through the company ha developed and launched an alternative product beginning in and based on the expected demand for the internally developed product the third party product the company doe not expect to use all of the product it will be required to buy resulting in loss on the purchase commitment letter of credit guarantee and other commitmentsoutstanding letter of credit and bank guarantee totaled million at december substantially all of these letter of credit and guarantee expire before outstanding surety bond and other guarantee totaled million at december the expiration of these bond and guarantee range through the letter of credit bank guarantee and surety bond principally secure performance obligation and allow the holder to draw fund up to the face amount of the letter of credit bank guarantee or surety bond if the applicable business unit doe not perform contractually required the company is guarantor of pension plan obligation of divested business the purchaser of the divested business ha agreed to pay for the pension benefit however the company wa required to guarantee payment of these pension benefit should the purchaser fail to do so the amount of the guarantee at december wa million in connection with the sale of business of the company the buyer have assumed certain contractual obligation of such business and have agreed to indemnify the company with respect to those assumed liability in the event third party to transferred contract doe not recognize the transfer of obligation or buyer default on it obligation under the transferred contract the company could be liable to the third party for such obligation however in such event the company would be entitled to seek indemnification from the buyer indemnificationsin conjunction with certain transaction primarily divestiture the company ha agreed to indemnify the other party with respect to certain liability related to the business that were sold or leased property that were abandoned retention of certain environmental tax employee and product liability the scope and duration of such indemnity obligation vary from transaction to transaction where probable an obligation for such indemnification is recorded liability generally maximum obligation can not be reasonably estimated other than obligation recorded liability at the time of divestiture historically the company ha not made significant payment for these indemnification in connection with the company effort to reduce the number of facility that it occupies the company ha vacated some of it leased facility or sublet them to third party when the company sublet facility to third party it remains the primary obligor under the master lease agreement with the owner of the facility result if third party vacates the sublet facility the company would be obligated to make lease or other payment under the master lease agreement the company belief that the financial risk of default by sublessors is individually and in the aggregate not material to the company financial position or result of operation in connection with the sale of product in the ordinary course of business the company often make representation affirming among other thing that it product do not infringe on the intellectual property right of others and agrees to indemnify customer against third party claim for such infringement the company ha not been required to make material payment under such provision environmental mattersthe company is currently involved in various stage of investigation and remediation related to environmental matter the company can not predict all potential cost related to environmental remediation matter and the possible impact on future fisher scientific inc note to consolidated financial statement continued operation given the uncertainty regarding the extent of the required cleanup the complexity and interpretation of applicable law and regulation the varying cost of alternative cleanup method and the extent of the company responsibility expense for environmental remediation matter related to the cost of installing operating and maintaining groundwater treatment system and other remedial activity related to historical environmental contamination at the company domestic and international facility were not material in any period presented the company record accrual for environmental remediation liability based on current interpretation of environmental law and regulation when it is probable that liability ha been incurred and the amount of such liability can be reasonably estimated the company calculates estimate based upon several factor including input from environmental specialist and management knowledge of and experience with these environmental matter the company includes in these estimate potential cost for investigation remediation and operation and maintenance of cleanup site at december the company total environmental liability wa approximately million while management belief the accrual for environmental remediation are adequate based on current estimate of remediation cost the company may be subject to additional remedial or compliance cost due to future event such change in existing law and regulation change in agency direction or enforcement policy development in remediation technology or change in the conduct of the company operation which could have material adverse effect on the company financial position result of operation or cash flow litigation and related contingenciesthe company is involved in various dispute governmental and or regulatory inspection inquiry investigation and proceeding and litigation matter that arise from time to time in the ordinary course of business the dispute and litigation matter include product liability intellectual property employment and commercial issue the company determines the probability and range of possible loss based on the current status of each of these matter liability is recorded in the financial statement if it is believed to be probable that loss ha been incurred and the amount of the loss can be reasonably estimated the company establishes liability that is an estimate of amount expected to be paid in the future for event that have already occurred the company accrues the most likely amount or at least the minimum of the range of probable loss when range of probable loss can be estimated the accrued liability are based on management judgment to the probability of loss for asserted and unasserted claim and where applicable actuarially determined estimate accrual estimate are adjusted additional information becomes known or payment are made the amount of ultimate loss may differ from these estimate due to the inherent uncertainty associated with pending litigation or claim the company can not predict the outcome nor with respect to certain pending litigation or claim where no liability ha been accrued make meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome the company ha no material accrual for pending litigation or claim for which accrual amount are not disclosed below nor are material loss deemed probable for such matter it is reasonably possible however that an unfavorable outcome that exceeds the company current accrual estimate if any for one or more of the matter described below could have material adverse effect on the company result of operation financial position and cash flow product liability worker compensation and other personal injury mattersthe range of probable loss for product liability worker compensation and other personal injury matter of the company continuing operation at december wa approximately million to million on an undiscounted basis the portion of these liability assumed in the merger with fisher wa recorded at it fair present value at the date of merger the company accrual for all such matter in total including the discounted liability wa million at december or million undiscounted the accrual includes estimated defense cost and is gross of estimated amount due from insurer of million at december or million undiscounted that are included in other asset in the accompanying balance sheet the portion of these insurance asset assumed in the merger with fisher wa also recorded at it fair value at the date of merger in addition to the above accrual of december the company had product liability accrual of million undiscounted relating to divested business although the company belief that the amount accrued and estimated recovery are probable and appropriate based on available information including actuarial study of loss estimate the process of estimating loss and insurance recovery involves considerable degree of judgment by management and the ultimate amount could vary materially insurance contract do not relieve the company of it primary obligation with respect to any loss incurred the collectability of amount due from it insurer is subject to the solvency and willingness of the insurer to pay well the legal sufficiency of the insurance claim management monitor the payment history well the financial condition and rating of it insurer on an ongoing basis fisher scientific inc note to consolidated financial statement continued note comprehensive income and shareholder equity comprehensive income loss comprehensive income combine net income and other comprehensive item other comprehensive item represent certain amount that are reported component of shareholder equity in the accompanying balance sheet change in each component of accumulated other comprehensive item net of tax are follows in million currencytranslationadjustmentunrealizedlosses onhedginginstrumentspension andotherpostretirementbenefitliabilityadjustmenttotalbalance at december other comprehensive item before reclassification amount reclassified from accumulated other comprehensive item net other comprehensive item balance at december shareholder equityat december the company had reserved million unissued share of it common stock for possible issuance under stock based compensation plan note fair value measurement and fair value of financial instrumentsfair value measurementsthe company us the market approach technique to value it financial instrument and there were no change in valuation technique during the company financial asset and liability carried at fair value are primarily comprised of insurance contract investment in derivative contract mutual fund holding publicly traded security and other investment in unit trust held asset to satisfy outstanding deferred compensation and retirement liability and acquisition related contingent consideration asset and liability carried at fair value are classified and disclosed in one of the following three category level quoted market price in active market for identical asset or liability that the company ha the ability to access level observable market based input or unobservable input that are corroborated by market data such quoted price interest rate and yield curve level input are unobservable data point that are not corroborated by market data the following table present information about the company financial asset and liability measured at fair value on recurring basis of december and december fisher scientific inc note to consolidated financial statement continued december quotedprices inactivemarketssignificantotherobservable inputssignificantunobservableinputs in million level level level assetscash equivalent investment in common stock mutual fund and other similar insurance derivative total asset liabilitiesderivative contract contingent total liability december quotedprices in activemarketssignificantotherobservable inputssignificant unobservable input in million level level level assetscash equivalent investment in common stock mutual fund and other similar insurance derivative total asset liabilitiesderivative contract contingent total liability the company us the black scholes model to value it warrant the company determines the fair value of it insurance contract by obtaining the cash surrender value of the contract from the issuer the fair value of derivative contract is the estimated amount that the company would receive pay upon liquidation of the contract taking into account the change in interest rate and currency exchange rate the company determines the fair value of acquisition related contingent consideration based on the probability weighted discounted cash flow associated with such future payment change to the fair value of contingent consideration are recorded in selling general and administrative expense the following table provides rollforward of the fair value determined by level input of the contingent consideration fisher scientific inc note to consolidated financial statement continued in million considerationbalance at beginning of year acquisition including assumed balance payment change in fair value included in earnings balance at end of year derivative contractsthe following table provides the aggregate notional value of outstanding derivative contract december december in million amountinterest rate swap fair value hedge described in note cross currency interest rate swap designated net investment currency exchange while certain derivative are subject to netting arrangement with counterparties the company doe not offset derivative asset and liability within the consolidated balance sheet the following table present the fair value of derivative instrument in the consolidated balance sheet and statement of income fair value assetsfair value liability december december december december in million designated hedging instrumentsinterest rate swap cross currency interest rate swap derivative not designated hedging instrumentscurrency exchange contract total derivative the fair value of the interest rate swap and cross currency interest rate swap are included in the consolidated balance sheet under the caption other asset or other long term liability the fair value of the currency exchange contract is included in the consolidated balance sheet under the caption other current asset or other accrued expense the following amount related to cumulative basis adjustment for fair value hedge were included in the consolidated balance sheet under the caption long term obligation carrying amount of the hedged liability cumulative amount of fair value hedging adjustment increase decrease included in carrying amount of liabilitydecember december december december in million term obligation fisher scientific inc note to consolidated financial statement continued gain loss recognized in million value hedging relationshipsinterest rate swapshedged long term obligation included in other expense net derivative designated hedging instrument included in other expense derivative designated cash flow hedgesinterest rate swapsincluded in unrealized loss on hedging instrument within other comprehensive item amount reclassified from accumulated other comprehensive item to other expense net financial instrument designated net investment hedgesforeign currency denominated debtincluded in currency translation adjustment within other comprehensive item cross currency interest rate swapsincluded in currency translation adjustment within other comprehensive item included in other expense derivative not designated hedging instrumentscurrency exchange contractsincluded in cost of product revenue included in other expense net cross currency interest rate swapsincluded in other expense net gain and loss recognized on currency exchange contract and the interest rate swap designated fair value hedge are included in the consolidated statement of income together with the corresponding offsetting loss and gain on the underlying hedged transaction the company us foreign currency denominated debt and cross currency interest rate swap to partially hedge it net investment in foreign operation against adverse movement in exchange rate the majority of the company euro denominated senior note and certain of it cross currency interest rate swap have been designated and are effective economic hedge of part of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument and contract fair value change on the cross currency interest rate swap excluding interest accrual are included in currency translation adjustment within other comprehensive item and shareholder equity in early the company entered into cross currency swap in anticipation of using dollar to partially finance the euro purchase price of then pending acquisition the swap were terminated later in the year in connection with the termination of the acquisition agreement gain and loss associated with these swap were recorded in other expense net the company had cash outflow of million associated with the termination of the swap included in other investing activity net in the accompany statement of cash flow see note and note for additional information on the company risk management objective and strategy cash flow hedge arrangementsin and the company entered into interest rate swap arrangement to mitigate the risk of interest rate rising prior to completion of debt offering based on the company conclusion that the debt offering were probable the swap hedged the cash flow risk for each of the interest payment on the planned fixed rate debt issue the aggregate fair value of the terminated hedge net of tax ha been classified reduction to accumulated other comprehensive item and will be amortized to interest expense over the term of the related debt issuance the company had cash outlay aggregating million and million in and respectively associated with termination of the arrangement included in other financing activity net in the accompanying statement of cash flow in late the company determined that the previously anticipated debt offering were probable of not occurring and reclassified million from accumulated other comprehensive item to other expense net fisher scientific inc note to consolidated financial statement continued fair value of other financial instrumentsthe carrying value and fair value of the company debt obligation are follows december in million valuevaluevaluevaluedebt obligation senior note the fair value of debt obligation wa determined based on quoted market price and on borrowing rate available to the company at the respective period end which represent level measurement note supplemental cash flow information in million paid for interest income non cash investing and financing activitiesacquired but unpaid property plant and declared but unpaid issuance of stock upon vesting of restricted stock cash cash equivalent and restricted cash is included in the consolidated balance sheet follows december december in million and cash equivalent restricted cash included in other current restricted cash included in other cash cash equivalent and restricted cash amount included in restricted cash represent fund held collateral for bank guarantee and incoming cash in china awaiting government administrative clearance fisher scientific inc note to consolidated financial statement continued note restructuring and other cost income net restructuring and other cost in primarily included continuing charge for headcount reduction and facility consolidation in an effort to streamline operation including the closure and consolidation of operation within several facility in the and europe and charge for the write off of acquired technology restructuring and other cost in also included transaction integration cost including reimbursement thereof related to recent terminated acquisition in severance action associated with facility consolidation and cost reduction measure affected approximately of the company workforce restructuring and other cost income net in primarily included the gain on the sale of the company anatomical pathology business and to lesser extent transaction integration cost related to acquisition and divestiture sale of inventory revalued at the date of acquisition and continuing charge for headcount reduction and facility consolidation in an effort to streamline operation including the closure and consolidation of operation within several facility in the and europe in severance action associated with facility consolidation and cost reduction measure affected approximately of the company workforce restructuring and other cost in included continuing charge for headcount reduction and facility consolidation in an effort to streamline operation including the closure and consolidation of operation within several facility in the and europe third party transaction integration cost primarily related to recent acquisition sale of inventory revalued at the date of acquisition and environmental remediation charge these charge were partially offset by gain on sale of real estate and favorable result of litigation in severance action associated with facility consolidation and cost reduction measure affected approximately of the company workforce of february the company ha identified restructuring action that will result in additional charge of approximately million primarily in and expects to identify additional action during which will be recorded when specified criterion are met such communication of benefit arrangement or when the cost have been incurred the company recorded net restructuring and other cost income by segment follows in million cost ofrevenuesselling general andadministrativeexpensesrestructuringand othercosts nettotallife science solution analytical instrument specialty diagnostics laboratory product and corporate the principal component of net restructuring and other cost income by segment are follows life science solutionsin the life science solution segment recorded million of net restructuring and other charge the segment recorded million of restructuring and other cost net primarily charge for the write off of acquired technology the segment also recorded million of credit to selling general and administrative expense for change in estimate of contingent acquisition consideration analytical instrumentsin the analytical instrument segment recorded million of net restructuring and other charge primarily for employee severance associated with headcount reduction in europe china and the and to lesser extent abandoned facility cost specialty diagnosticsf fisher scientific inc note to consolidated financial statement continued in the specialty diagnostics segment recorded million of net restructuring and other income principally for third party transaction cost including reimbursement thereof for terminated acquisition partially offset by charge for employee severance and environmental remediation at previously owned facility laboratory product and servicesin the laboratory product and service segment recorded million of net restructuring and other charge primarily for employee severance at business streamlining operation write down of fixed asset to estimated disposal value in connection with the consolidation of commercial production operation in the and to lesser extent transaction acquisition related cost for pending acquisition corporatein the company recorded million of net restructuring and other cost primarily for severance at it corporate operation and charge to selling general and administrative expense for product liability litigation the company recorded net restructuring and other cost by segment follows in million cost ofrevenuesselling general andadministrativeexpensesrestructuringand othercosts income nettotallife science solution analytical instrument specialty diagnostics laboratory product and corporate the principal component of net restructuring and other cost by segment are follows life science solutionsin the life science solution segment recorded million of net restructuring and other charge including million of charge to cost of revenue for the sale of inventory revalued at the date of acquisition the segment also recorded million of net restructuring and other charge for severance and other cost associated with facility consolidation in the and europe the impairment of acquired technology in development and pre acquisition litigation related matter analytical instrumentsin the analytical instrument segment recorded million of net restructuring and other charge including million of charge to selling general and administrative expense principally third party transaction cost for terminated acquisition the segment also recorded million of restructuring and other cost primarily for employee severance and other cost associated with facility consolidation in the and europe specialty diagnosticsin the specialty diagnostics segment recorded million of net restructuring and other income primarily gain on the divestiture of it anatomical pathology business note the segment also recorded million of charge to selling general and administrative expense principally third party transaction cost in connection with the sale of the anatomical pathology business laboratory product and servicesin the laboratory product and service segment recorded million of net restructuring and other charge the segment recorded million of charge to selling general and administrative expense principally third party transaction integration cost for recently completed acquisition the segment also recorded million of restructuring and other cost primarily charge for severance at business streamlining operation and employee compensation due at brammer bio on the date of acquisition fisher scientific inc note to consolidated financial statement continued the company recorded net restructuring and other cost by segment follows in million cost ofrevenuesselling general andadministrativeexpensesrestructuringand othercosts nettotallife science solution analytical specialty diagnostics laboratory product and corporate the principal component of net restructuring and other cost by segment are follows life science solutionsin the life science solution segment recorded million of net restructuring and other income the segment recorded charge to cost of revenue of million for the sale of inventory revalued at the date of acquisition well million of charge to selling general and administrative expense primarily third party transaction integration cost related to recent acquisition the segment also recorded million of net restructuring and other income principally for million net gain on the resolution of litigation partially offset by charge for severance other cost associated with facility consolidation in the analytical instrumentsin the analytical instrument segment recorded million of net restructuring and other charge the segment recorded net charge to cost of revenue of million for the sale of inventory revalued at the date of acquisition million of net charge to selling general and administrative expense principally third party transaction cost for pending acquisition and million of restructuring and other cost primarily for employee severance and other cost associated with facility consolidation in the and europe well abandoned facility cost associated with the remediation and closure of manufacturing facility in the specialty diagnosticsin the specialty diagnostics segment recorded million of net restructuring and other charge including million of net charge to selling general and administrative expense principally third party transaction cost in connection with the planned sale of the anatomical pathology business the segment also recorded million of net restructuring and other income including million gain on the sale of real estate mostly offset by cash charge for severance and other cost associated with facility consolidation in the and europe laboratory product and servicesin the laboratory product and service segment recorded million of net restructuring and other charge the segment recorded charge to cost of revenue of million principally for the sale of inventory revalued at the date of acquisition and million of charge to selling general and administrative expense for third party transaction integration cost related to the acquisition of patheon the segment also recorded million of restructuring and other cost primarily charge for environmental remediation associated with superfund site in the employee severance and to lesser extent hurricane response cost the following table summarizes the change in the company accrued restructuring balance other amount reported restructuring and other cost net in the accompanying statement of income have been summarized in the note to the table accrued restructuring cost are included in other accrued expense in the accompanying balance sheet fisher scientific inc note to consolidated financial statement continued in million total balance at december net restructuring charge incurred in payment currency translation balance at december cumulative effect of accounting change net restructuring charge incurred in payment currency translation balance at december net restructuring charge incurred in payment currency translation and other balance at december the movement in the restructuring liability principally consist of severance and other cost such relocation and moving expense associated with facility consolidation well employee retention cost which are accrued ratably over the period through which employee must work to qualify for payment and in abandoned facility cost associated with facility consolidation in the excludes million of income net associated with litigation related matter gain on sale of real estate charge for environmental remediation and hurricane response cost impact of adopting new lease accounting guidance on january excludes million of net gain on the sale of business and million of other restructuring charge net primarily for the write off of acquired technology pre acquisition litigation related matter and compensation due to employee on the date of acquisition excludes million of other restructuring charge net primarily for the write off of acquired technology fixed asset writedowns and cost associated with environmental remediation at abandoned previously owned facility the company expects to pay accrued restructuring cost primarily through note subsequent event acquisitionson january the company acquired within the laboratory product and service segment the belgium based european viral vector manufacturing business of groupe novasep sa for approximately million in cash the european viral vector manufacturing business provides contract manufacturing service for vaccine and therapy to biotechnology company and large biopharma customer the acquisition expands the segment capability for cell and gene vaccine and therapy the initial purchase price allocation for the acquisition is expected to be completed by the end of the first quarter of on january the company entered into definitive agreement to acquire mesa biotech inc based molecular diagnostic company for approximately million in cash and up to an additional million in cash upon the completion of certain milestone following the close of the transaction mesa biotech ha developed and commercialized pcr based rapid point of care testing platform available for detecting infectious disease including sars cov influenza and respiratory syncytial virus and strep the acquisition will enable the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care the transaction is expected to be completed in the first quarter of subject to customary closing condition upon completion the business will become part of the life science solution segment